- en: <!--yml
  id: totrans-0
  prefs: []
  type: TYPE_NORMAL
  zh: <!--yml
- en: 'category: 未分类'
  id: totrans-1
  prefs: []
  type: TYPE_NORMAL
  zh: 类别：未分类
- en: 'date: 2025-01-11 11:54:17'
  id: totrans-2
  prefs: []
  type: TYPE_NORMAL
  zh: 日期：2025-01-11 11:54:17
- en: -->
  id: totrans-3
  prefs: []
  type: TYPE_NORMAL
  zh: -->
- en: 'Regulator-Manufacturer AI Agents Modeling: Mathematical Feedback-Driven Multi-Agent
    LLM Framework'
  id: totrans-4
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 监管者-制造商AI智能体建模：基于数学反馈驱动的多智能体LLM框架
- en: 来源：[https://arxiv.org/html/2411.15356/](https://arxiv.org/html/2411.15356/)
  id: totrans-5
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 来源：[https://arxiv.org/html/2411.15356/](https://arxiv.org/html/2411.15356/)
- en: Yu Han These authors contributed equally to this work. Department of Engineering
    Science, University of Oxford, United Kingdom
  id: totrans-6
  prefs: []
  type: TYPE_NORMAL
  zh: Yu Han 这些作者对本研究贡献相等。牛津大学工程科学系，英国
- en: yu.han@eng.ox.ac.uk Zekun Guo Data Science, Artificial Intelligence and Modelling
    Center, University of Hull, United Kingdom
  id: totrans-7
  prefs: []
  type: TYPE_NORMAL
  zh: yu.han@eng.ox.ac.uk Zekun Guo 数据科学、人工智能与建模中心，赫尔大学，英国
- en: Z.Guo2@hull.ac.uk
  id: totrans-8
  prefs: []
  type: TYPE_NORMAL
  zh: Z.Guo2@hull.ac.uk
- en: Abstract
  id: totrans-9
  prefs:
  - PREF_H6
  type: TYPE_NORMAL
  zh: 摘要
- en: The increasing complexity of regulatory updates from global authorities presents
    significant challenges for medical device manufacturers, necessitating agile strategies
    to sustain compliance and maintain market access. Concurrently, regulatory bodies
    must effectively monitor manufacturers’ responses and develop strategic surveillance
    plans. This study employs a multi-agent modeling approach, enhanced with Large
    Language Models (LLMs), to simulate regulatory dynamics and examine the adaptive
    behaviors of key actors, including regulatory bodies, manufacturers, and competitors.
    These agents operate within a simulated environment governed by regulatory flow
    theory, capturing the impacts of regulatory changes on compliance decisions, market
    adaptation, and innovation strategies. Our findings illuminate the influence of
    regulatory shifts on industry behavior and identify strategic opportunities for
    improving regulatory practices, optimizing compliance, and fostering innovation.
    By leveraging the integration of multi-agent systems and LLMs, this research provides
    a novel perspective and offers actionable insights for stakeholders navigating
    the evolving regulatory landscape of the medical device industry.
  id: totrans-10
  prefs: []
  type: TYPE_NORMAL
  zh: 全球监管机构日益复杂的监管更新为医疗设备制造商带来了重大挑战，迫切需要灵活的策略以保持合规性并确保市场准入。同时，监管机构必须有效监控制造商的应对措施，并制定战略性的监管计划。本研究采用多智能体建模方法，并结合大型语言模型（LLMs）模拟监管动态，探讨关键角色（包括监管机构、制造商和竞争者）的适应性行为。这些智能体在一个由监管流动理论控制的模拟环境中运作，捕捉监管变化对合规决策、市场适应和创新战略的影响。我们的研究结果揭示了监管变化对行业行为的影响，并识别出改进监管实践、优化合规性以及促进创新的战略机会。通过融合多智能体系统和LLM，本研究提供了一种新颖的视角，并为在医疗设备行业不断变化的监管环境中导航的利益相关者提供了可操作的见解。
- en: 'Index terms: Multi Agents, LLM, Transcendental Equation, Regulatory Science'
  id: totrans-11
  prefs: []
  type: TYPE_NORMAL
  zh: 关键词：多智能体，LLM，超越方程，监管科学
- en: 1 Introduction
  id: totrans-12
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 1 引言
- en: 1.1 Adaptive Dynamics and Emergent Behaviors in Regulatory Affairs
  id: totrans-13
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 1.1 监管事务中的适应性动态与突现行为
- en: The ongoing issuance of guidance documents by global medical products regulatory
    authorities such as the Food and Drug Administration (FDA) reflects an increasing
    commitment to public health and safety in response to fast-paced technological
    advancements. These proactive regulatory actions are aimed at ensuring that new
    medical devices meet high standards for efficacy and safety. However, as regulatory
    bodies accelerate the release of new guidelines, medical device manufacturers
    face mounting pressure to interpret, implement, and comply with updated standards
    promptly [[1](https://arxiv.org/html/2411.15356v2#bib.bib1)]. The ability to swiftly
    adapt to these changes is essential for maintaining market access and ensuring
    compliance with evolving regulatory expectations [[2](https://arxiv.org/html/2411.15356v2#bib.bib2)],
    [[3](https://arxiv.org/html/2411.15356v2#bib.bib3)].
  id: totrans-14
  prefs: []
  type: TYPE_NORMAL
  zh: 全球医疗产品监管机构（如美国食品和药物管理局（FDA））持续发布指导文件，反映了其对公共健康与安全日益增加的关注，以应对快速发展的技术进步。这些积极的监管举措旨在确保新医疗设备达到高标准的疗效和安全性。然而，随着监管机构加速发布新指南，医疗设备制造商面临着越来越大的压力，需要迅速解读、实施并遵守更新的标准[[1](https://arxiv.org/html/2411.15356v2#bib.bib1)]。快速适应这些变化的能力对于保持市场准入和确保遵守不断变化的监管期望至关重要[[2](https://arxiv.org/html/2411.15356v2#bib.bib2)]，[[3](https://arxiv.org/html/2411.15356v2#bib.bib3)]。
- en: In regulatory systems, emergent behaviors are evident when new regulations trigger
    adaptive responses across various stakeholders, including manufacturers, regulatory
    agencies, and healthcare providers [[4](https://arxiv.org/html/2411.15356v2#bib.bib4)].
    These responses can lead to substantial shifts in compliance practices and innovation
    trajectories. Regulatory interactions are often nonlinear, meaning that small
    changes in regulations can produce disproportionately large effects on behavior
    and system-wide outcomes [[5](https://arxiv.org/html/2411.15356v2#bib.bib5)].
    Stakeholders within these systems continually adjust their strategies to align
    with evolving regulatory standards, highlighting the self-organizing nature of
    regulatory systems [[6](https://arxiv.org/html/2411.15356v2#bib.bib6)]. Through
    decentralized decision-making, these systems can lead to the spontaneous emergence
    of best practices and industry standards [[7](https://arxiv.org/html/2411.15356v2#bib.bib7)].
  id: totrans-15
  prefs: []
  type: TYPE_NORMAL
  zh: 在监管系统中，当新法规触发各方利益相关者（包括制造商、监管机构和医疗服务提供者）的适应性反应时，常常表现出突现行为[[4](https://arxiv.org/html/2411.15356v2#bib.bib4)]。这些反应可能导致合规实践和创新轨迹的显著变化。监管互动通常是非线性的，这意味着法规的细微变化可能对行为和系统范围的结果产生不成比例的巨大影响[[5](https://arxiv.org/html/2411.15356v2#bib.bib5)]。这些系统中的利益相关者不断调整其策略，以与不断变化的监管标准保持一致，这突显了监管系统自组织的特性[[6](https://arxiv.org/html/2411.15356v2#bib.bib6)]。通过去中心化的决策，这些系统能够促使最佳实践和行业标准的自发产生[[7](https://arxiv.org/html/2411.15356v2#bib.bib7)]。
- en: 'Despite the importance of understanding these dynamics, a significant gap exists
    in current research, where most studies focus on regulatory frameworks or compliance
    outcomes in isolation. This gap leaves essential questions unanswered: How do
    continuous regulatory updates impact manufacturers’ decision-making processes,
    and what adaptive strategies can support both compliance and innovation in this
    fast-evolving landscape [[8](https://arxiv.org/html/2411.15356v2#bib.bib8)]?'
  id: totrans-16
  prefs: []
  type: TYPE_NORMAL
  zh: 尽管理解这些动态至关重要，但当前研究中存在一个显著的空白，大多数研究集中于监管框架或合规结果的单独分析。这个空白留下了许多关键问题尚未解答：持续的监管更新如何影响制造商的决策过程？在这个快速变化的环境中，什么样的适应性策略能够同时支持合规性和创新[[8](https://arxiv.org/html/2411.15356v2#bib.bib8)]？
- en: This study aims to address this research gap by introducing a comprehensive
    model that uses LLM agents to capture the cyclical interactions between regulatory
    authorities and medical device manufacturers. By simulating the relationships
    and feedback loops among regulatory bodies, manufacturers, and the responses triggered
    when manufacturer agents ”review” a set of 10 regulatory guidelines—followed by
    the regulator agent’s decision on whether to approve the submissions—this approach
    provides an innovative angle within regulatory systems. It also offers practical
    guidance for both regulatory bodies and manufacturers in developing agile and
    responsive compliance strategies.
  id: totrans-17
  prefs: []
  type: TYPE_NORMAL
  zh: 本研究旨在通过引入一个综合模型来填补这一研究空白，该模型利用大型语言模型（LLM）代理捕捉监管机构与医疗设备制造商之间的循环互动。通过模拟监管机构、制造商之间的关系及其反馈回路，当制造商代理“审查”一套10条监管指南后，监管代理决定是否批准这些提交的过程，这一方法为监管系统提供了创新视角。它还为监管机构和制造商在制定灵活且响应迅速的合规策略方面提供了实际指导。
- en: 1.2 Multi-Agent Modeling and Complexity Theory
  id: totrans-18
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 1.2 多代理建模与复杂性理论
- en: Multi-agent modeling offer a powerful approach for simulating complex systems
    with autonomous, interacting agents [[9](https://arxiv.org/html/2411.15356v2#bib.bib9)].
    In land-use and land-cover change (LUCC) modeling, MAS combines cellular landscape
    models with agent-based decision-making representations, effectively capturing
    spatial interactions and decentralized decision-making [[10](https://arxiv.org/html/2411.15356v2#bib.bib10),
    [11](https://arxiv.org/html/2411.15356v2#bib.bib11)]. These models are particularly
    useful for representing heterogeneous conditions and human-environment interactions,
    ranging from abstract hypotheses to detailed policy analyses. Recent advancements
    have extended MAS to the multimodal domain, leveraging large language models (LLMs)
    to create large multimodal agents (LMAs) capable of interpreting and responding
    to diverse user queries [[12](https://arxiv.org/html/2411.15356v2#bib.bib12)].
    LMAs enhance AI agents’ ability to handle complex tasks by integrating multiple
    modalities. However, standardized evaluation methods are needed to facilitate
    meaningful comparisons among different LMAs and guide future research in this
    rapidly evolving field [[13](https://arxiv.org/html/2411.15356v2#bib.bib13)].
  id: totrans-19
  prefs: []
  type: TYPE_NORMAL
  zh: 多代理建模提供了一种强有力的方法，用于模拟由自主交互代理组成的复杂系统[[9](https://arxiv.org/html/2411.15356v2#bib.bib9)]。在土地利用和土地覆盖变化（LUCC）建模中，MAS将细胞景观模型与基于代理的决策表示结合，能够有效地捕捉空间交互和分散式决策[[10](https://arxiv.org/html/2411.15356v2#bib.bib10),
    [11](https://arxiv.org/html/2411.15356v2#bib.bib11)]。这些模型特别适用于表示异质条件和人类与环境的交互，涵盖从抽象假设到详细的政策分析。近期的进展已将MAS扩展到多模态领域，通过利用大型语言模型（LLMs）创建大型多模态代理（LMAs），使其能够解读并回应多样化的用户查询[[12](https://arxiv.org/html/2411.15356v2#bib.bib12)]。LMAs通过整合多种模态，增强了AI代理处理复杂任务的能力。然而，需要标准化的评估方法，以便在不同LMAs之间进行有意义的比较，并指导这一快速发展的领域的未来研究[[13](https://arxiv.org/html/2411.15356v2#bib.bib13)]。
- en: Multi-agent modeling (MAM) offers a powerful approach to simulate complex systems
    comprising multiple autonomous agents with interactive behaviors. This strength
    is particularly suited for examining dynamic and emergent properties in systems
    where agents—such as manufacturers and regulatory bodies, continuously adjust
    their behaviors based on interactions with one another and with their environment
    [[14](https://arxiv.org/html/2411.15356v2#bib.bib14)]. This bottom-up approach
    enables researchers to study how localized actions and interactions scale into
    broader system-wide outcomes, making MAM an effective tool for understanding regulatory
    environments characterized by unpredictability and non-linearity [[15](https://arxiv.org/html/2411.15356v2#bib.bib15)].
  id: totrans-20
  prefs: []
  type: TYPE_NORMAL
  zh: 多代理建模（MAM）提供了一种强有力的方法，用于模拟由多个自主代理组成的复杂系统，这些代理具有交互行为。这一优势特别适用于研究系统中的动态和涌现特性，在这些系统中，代理——如制造商和监管机构——根据相互之间以及与环境的互动不断调整其行为[[14](https://arxiv.org/html/2411.15356v2#bib.bib14)]。这种自下而上的方法使研究人员能够研究局部行动和互动如何扩展为更广泛的系统结果，从而使MAM成为理解具有不可预测性和非线性特征的监管环境的有效工具[[15](https://arxiv.org/html/2411.15356v2#bib.bib15)]。
- en: At the foundation of multi-agent modeling lies Complexity Theory, which provides
    a framework for analyzing systems where interconnected components exhibit emergent
    behaviors. Complexity Theory suggests that even small regulatory adjustments can
    lead to disproportionately large shifts in stakeholder behavior, highlighting
    the importance of adaptability within regulatory frameworks [[16](https://arxiv.org/html/2411.15356v2#bib.bib16)].
    In regulatory systems, such adaptability materializes through a continuous cycle
    of response, where stakeholders dynamically adjust to regulatory changes, and
    these adjustments subsequently influence the development of future standards through
    feedback loops.
  id: totrans-21
  prefs: []
  type: TYPE_NORMAL
  zh: 多代理建模的基础是复杂性理论，它为分析互联组件表现出涌现行为的系统提供了框架。复杂性理论表明，即使是小的监管调整也可能导致利益相关者行为的巨大变化，这凸显了在监管框架中适应性的重要性[[16](https://arxiv.org/html/2411.15356v2#bib.bib16)]。在监管系统中，这种适应性通过一个持续的响应循环实现，其中利益相关者动态调整对监管变化的反应，而这些调整随后通过反馈回路影响未来标准的发展。
- en: 'Regulatory Flow Theory, which contextualizes MAM in this study, visualizes
    regulatory interactions as currents within a river, guiding stakeholders’ actions.
    This theory conceptualizes the regulatory landscape as a continuous flow, where
    each regulatory update acts as a current shaping compliance behavior, strategic
    planning, and industry innovation. Regulatory Flow Theory captures the cyclical
    nature of these systems: an initial regulatory document prompts adaptive actions
    by manufacturers, who then provide feedback that informs further updates. This
    feedback mechanism creates an evolving regulatory environment, enabling both regulators
    and manufacturers to respond flexibly to emerging challenges [[17](https://arxiv.org/html/2411.15356v2#bib.bib17),
    [18](https://arxiv.org/html/2411.15356v2#bib.bib18)]. For regulatory bodies, recognizing
    the emergent properties of these systems can inform the development of more adaptive
    and responsive frameworks. For manufacturers, appreciating the complex interactions
    within the regulatory landscape can enhance strategic planning, enabling them
    to remain agile and compliant amidst regulatory shifts. This research models the
    regulatory affairs process, including the issuance of regulations, manufacturers’
    adaptive compliance efforts, and the influence of stakeholder feedback on regulatory
    authorities. Ultimately, it aims to explore the balance of delivering safe medical
    devices to patients without stifling innovation—a nuanced challenge underexplored
    within Regulatory Sciences.'
  id: totrans-22
  prefs: []
  type: TYPE_NORMAL
  zh: 本研究中的MAM背景下的《监管流理论》将监管互动可视化为河流中的水流，引导利益相关者的行为。该理论将监管环境概念化为一个持续流动的过程，其中每一次监管更新都如同水流一样，塑造着合规行为、战略规划和行业创新。《监管流理论》捕捉到了这些系统的循环特性：初始的监管文件促使制造商采取适应性行动，制造商随后提供反馈，这些反馈又为进一步的更新提供了依据。这个反馈机制创造了一个不断发展的监管环境，使得监管机构和制造商能够灵活应对新出现的挑战[[17](https://arxiv.org/html/2411.15356v2#bib.bib17)，[18](https://arxiv.org/html/2411.15356v2#bib.bib18)]。对于监管机构来说，认识到这些系统的涌现特性可以为制定更具适应性和响应性的框架提供参考。对于制造商而言，理解监管环境中复杂的互动关系可以提升战略规划，使他们能够在监管变动中保持灵活和合规。本研究对监管事务流程进行了建模，包括法规的发布、制造商的适应性合规努力以及利益相关者反馈对监管机构的影响。最终，研究旨在探讨如何在不抑制创新的情况下向患者提供安全的医疗设备——这一在监管科学领域中尚未得到充分探讨的复杂挑战。
- en: 2 Literature Review
  id: totrans-23
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 2 文献综述
- en: Regulatory authorities are responsible for establishing regulations and guidelines
    that define new methods, standards, and models to ensure that medical products
    meet stringent criteria for safety, efficacy, quality, and performance. The field
    of regulatory affairs is pivotal in overseeing these medical products, working
    to protect public health by verifying that all products brought to market are
    both safe and effective [[19](https://arxiv.org/html/2411.15356v2#bib.bib19)].
    Situated at the intersection of engineering and medicine, regulatory science addresses
    the increasingly complex challenges associated with medical product innovation
    and oversight [[20](https://arxiv.org/html/2411.15356v2#bib.bib20)]. Over the
    past few decades, the regulatory landscape for medical products has evolved significantly
    [[3](https://arxiv.org/html/2411.15356v2#bib.bib3)], [[21](https://arxiv.org/html/2411.15356v2#bib.bib21)].
    This transformation has been driven by the need to strike a delicate balance between
    maintaining high safety standards and fostering innovation to accommodate rapid
    technological advancements. To advance regulatory practices, researchers are exploring
    innovative approaches that span from the optimization of language and communication
    strategies [[22](https://arxiv.org/html/2411.15356v2#bib.bib22)] to the integration
    of artificial intelligence and advanced modeling techniques [[1](https://arxiv.org/html/2411.15356v2#bib.bib1)].
    These advancements aim to enhance regulatory efficiency, improve the interpretation
    of complex guidelines, and facilitate adaptive regulatory frameworks that keep
    pace with emerging technologies.
  id: totrans-24
  prefs: []
  type: TYPE_NORMAL
  zh: 监管机构负责制定规定和指南，定义新的方法、标准和模型，以确保医疗产品符合严格的安全性、有效性、质量和性能标准。监管事务领域在监管这些医疗产品方面起着关键作用，致力于通过验证市场上所有产品的安全性和有效性来保护公共健康
    [[19](https://arxiv.org/html/2411.15356v2#bib.bib19)]。监管科学位于工程学与医学的交叉点，解决与医疗产品创新和监管相关的日益复杂的挑战
    [[20](https://arxiv.org/html/2411.15356v2#bib.bib20)]。在过去的几十年中，医疗产品的监管环境发生了显著变化
    [[3](https://arxiv.org/html/2411.15356v2#bib.bib3)], [[21](https://arxiv.org/html/2411.15356v2#bib.bib21)]。这一转变的推动力是需要在维持高安全标准与促进创新之间取得微妙的平衡，以适应快速发展的技术进步。为了推动监管实践，研究人员正在探索创新方法，涵盖从优化语言和沟通策略
    [[22](https://arxiv.org/html/2411.15356v2#bib.bib22)] 到人工智能和先进建模技术的整合 [[1](https://arxiv.org/html/2411.15356v2#bib.bib1)]。这些进展旨在提高监管效率、改善复杂指南的解读，并促进能够跟上新兴技术步伐的适应性监管框架。
- en: In the field of Regulatory Science, previous modeling efforts have primarily
    focused on evaluating the safety and effectiveness of individual categories of
    medical products. Typically, these models are developed for a specific type of
    pharmaceutical product that shares a common target or mechanism of action, requiring
    a high degree of precision tailored to the unique characteristics of that product
    category. Examples include models like the Physiologically Based Pharmacokinetic
    (PBPK) Absorption Model for oral capsules [[23](https://arxiv.org/html/2411.15356v2#bib.bib23)],
    clinical decision support systems integrated into medical devices [[24](https://arxiv.org/html/2411.15356v2#bib.bib24)],
    and models that leverage real-world evidence throughout the entire product lifecycle
    [[25](https://arxiv.org/html/2411.15356v2#bib.bib25)]. Additionally, novel analytical
    technologies have been developed to improve the detection and assessment of medical
    products [[26](https://arxiv.org/html/2411.15356v2#bib.bib26)].
  id: totrans-25
  prefs: []
  type: TYPE_NORMAL
  zh: 在监管科学领域，以往的建模工作主要集中在评估各类医疗产品的安全性和有效性。通常，这些模型是为特定类型的药品产品开发的，这些产品具有共同的靶点或作用机制，需要针对该产品类别的独特特性进行高度精准的定制。例如，诸如生理基础药代动力学（PBPK）吸收模型用于口服胶囊
    [[23](https://arxiv.org/html/2411.15356v2#bib.bib23)]、集成到医疗设备中的临床决策支持系统 [[24](https://arxiv.org/html/2411.15356v2#bib.bib24)]，以及利用真实世界证据贯穿整个产品生命周期的模型
    [[25](https://arxiv.org/html/2411.15356v2#bib.bib25)]。此外，还开发了新型分析技术，以改善医疗产品的检测和评估
    [[26](https://arxiv.org/html/2411.15356v2#bib.bib26)]。
- en: From a broader process perspective, considering the development of medical products
    and their impact on global public health, various other types of models have been
    designed to streamline regulatory processes and improve compliance. A foundational
    model in this domain is the risk management Model, which gained prominence following
    the introduction of the ICH Q9 guidelines. This model emphasizes the identification,
    assessment, and mitigation of risks throughout both the drug development and post-market
    phases, offering a framework that aligns regulatory oversight with public safety
    objectives [[27](https://arxiv.org/html/2411.15356v2#bib.bib27)], [[28](https://arxiv.org/html/2411.15356v2#bib.bib28)].
    Research has shown that risk-based regulation enhances regulatory outcomes by
    prioritizing resources and focusing on the most critical risk factors [[29](https://arxiv.org/html/2411.15356v2#bib.bib29)].
  id: totrans-26
  prefs: []
  type: TYPE_NORMAL
  zh: 从更广泛的过程视角来看，考虑到医疗产品的发展及其对全球公共卫生的影响，已经设计了各种其他类型的模型，以简化监管过程并改善合规性。该领域的一个基础模型是风险管理模型，该模型在引入ICH
    Q9指南后获得了广泛关注。该模型强调在药物开发和市场后阶段识别、评估和减轻风险，提供了一个将监管监督与公共安全目标对接的框架[[27](https://arxiv.org/html/2411.15356v2#bib.bib27)],
    [[28](https://arxiv.org/html/2411.15356v2#bib.bib28)]。研究表明，基于风险的监管通过优先配置资源并聚焦于最关键的风险因素，从而提高了监管结果[[29](https://arxiv.org/html/2411.15356v2#bib.bib29)]。
- en: Another pillar of modeling in Regulatory Science is the Lifecycle Management
    Model, which conceptualizes drug regulation as a continuous process encompassing
    development, market approval, and post-market surveillance. This model’s strength
    lies in its ability to uphold drug quality and safety across the entire product
    lifecycle, adapting to emerging concerns through responsive and flexible regulatory
    mechanisms [[30](https://arxiv.org/html/2411.15356v2#bib.bib30)]. Additionally,
    economic analysis serves as another pillar, with the Cost-Benefit Analysis Model
    providing a quantitative method to evaluate the economic impacts of new regulations.
    This approach allows regulators to balance public health benefits against the
    financial costs to the pharmaceutical industry, fostering rational and balanced
    decision-making [[31](https://arxiv.org/html/2411.15356v2#bib.bib31)], [[32](https://arxiv.org/html/2411.15356v2#bib.bib32)].
  id: totrans-27
  prefs: []
  type: TYPE_NORMAL
  zh: 监管科学建模的另一个支柱是生命周期管理模型，该模型将药物监管概念化为一个持续的过程，包括开发、市场批准和市场后监管。该模型的优势在于能够在整个产品生命周期内维护药物的质量和安全，并通过响应性和灵活的监管机制适应新出现的问题[[30](https://arxiv.org/html/2411.15356v2#bib.bib30)]。此外，经济分析作为另一个支柱，通过成本效益分析模型提供了一种定量方法来评估新监管措施的经济影响。这种方法使监管者能够权衡公共卫生利益与制药行业的财务成本，从而促进理性和平衡的决策[[31](https://arxiv.org/html/2411.15356v2#bib.bib31)],
    [[32](https://arxiv.org/html/2411.15356v2#bib.bib32)]。
- en: However, in the field of regulatory science, dynamic modeling that captures
    the intricate relationships among regulators, manufacturers, and the regulatory
    content they release remains largely underexplored. Understanding how manufacturers
    respond to regulatory guidelines and adapt their practices is crucial for optimizing
    compliance and fostering innovation. To address this gap, Regulatory Flow Theory,
    a novel model supported by the Transcendence Equation, has been introduced. This
    model mathematically represents the feedback and adaptation mechanisms among key
    stakeholders in the regulatory landscape. Specifically, the equations describe
    how key variables such as regulatory influence, compliance effort, market adaptation,
    and feedback interact over time. By formalizing these relationships, the model
    provides a nuanced understanding of how regulatory decisions impact industry behavior
    and compliance strategies.
  id: totrans-28
  prefs: []
  type: TYPE_NORMAL
  zh: 然而，在监管科学领域，捕捉监管者、制造商和他们发布的监管内容之间复杂关系的动态建模仍然未得到充分探讨。了解制造商如何响应监管指南并调整其实践，对于优化合规性和促进创新至关重要。为了解决这一空白，提出了监管流动理论，这是一种由超越方程支持的新模型。该模型数学地表示了监管环境中主要利益相关者之间的反馈和适应机制。具体而言，这些方程描述了监管影响、合规努力、市场适应和反馈等关键变量如何随时间相互作用。通过形式化这些关系，该模型提供了对监管决策如何影响行业行为和合规策略的细致理解。
- en: The development for such dynamic equation was historically hindered in the past,
    primarily due to the difficulty in capturing and experimentally validating the
    intricate relationships. However, with the advent of Large Language Models (LLMs),
    which significantly expanded the potential for dynamic modeling. Integrating LLMs
    within multi-agent frameworks [[9](https://arxiv.org/html/2411.15356v2#bib.bib9)]
    offers a promising approach for optimizing complex engineering systems. In these
    frameworks, agents are assigned distinct roles, and through role-playing interactions,
    they simulate the behaviors of various entities. The multi-agent system consists
    of numerous interacting agents that collaborate or compete to achieve specific
    objectives [[33](https://arxiv.org/html/2411.15356v2#bib.bib33)].
  id: totrans-29
  prefs: []
  type: TYPE_NORMAL
  zh: 这种动态方程的发展在历史上曾受到阻碍，主要是由于捕捉和实验验证复杂关系的困难。然而，随着大型语言模型（LLMs）的出现，它大大扩展了动态建模的潜力。将LLMs整合到多智能体框架中[[9](https://arxiv.org/html/2411.15356v2#bib.bib9)]提供了一种优化复杂工程系统的有前景的方法。在这些框架中，智能体被分配不同的角色，通过角色扮演互动，它们模拟各种实体的行为。多智能体系统由多个相互作用的智能体组成，这些智能体通过合作或竞争实现特定目标[[33](https://arxiv.org/html/2411.15356v2#bib.bib33)]。
- en: Multi-Agent Models have the potential to revolutionize regulatory processes
    by enabling autonomous agents, each representing a different stakeholder or regulatory
    entity, to interact and make decisions collaboratively. These agents, equipped
    with LLM capabilities, can interpret regulatory texts, process real-time data,
    and respond dynamically to changes in the regulatory environment. Moreover, the
    use of mathematical feedback mechanisms within these models allows for more adaptive
    and responsive decision-making, a critical advancement in managing complex regulatory
    ecosystems. The promise of multi-agent systems in regulatory contexts lies in
    their ability to facilitate collaboration, enhance real-time decision-making,
    and scale to accommodate diverse regulatory requirements. By leveraging LLMs for
    feedback-driven optimization, these models can deliver predictive insights previously
    unattainable, effectively addressing emerging regulatory challenges in ways that
    traditional approaches cannot [[34](https://arxiv.org/html/2411.15356v2#bib.bib34)].
    The potential for such models to transform regulatory practices is substantial,
    offering a more proactive, data-driven, and adaptable framework for oversight,
    particularly in the medical industry.
  id: totrans-30
  prefs: []
  type: TYPE_NORMAL
  zh: 多智能体模型有潜力通过使每个代表不同利益相关者或监管实体的自主智能体互动并协作决策，彻底改变监管过程。这些配备LLM能力的智能体可以解读监管文本、处理实时数据，并动态响应监管环境的变化。此外，这些模型中使用的数学反馈机制使得决策更加适应性强和响应迅速，这是管理复杂监管生态系统的重要进展。在监管环境中，多智能体系统的潜力在于它们能够促进协作、增强实时决策能力，并扩展以适应多样化的监管要求。通过利用LLMs进行基于反馈的优化，这些模型能够提供以前无法获得的预测性见解，有效地应对传统方法无法解决的新兴监管挑战[[34](https://arxiv.org/html/2411.15356v2#bib.bib34)]。这种模型改变监管实践的潜力是巨大的，特别是在医疗行业，提供了一个更加主动、数据驱动和适应性强的监督框架。
- en: 3 Methodology
  id: totrans-31
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 3 方法论
- en: Our study employed Large Language Models (LLMs) to simulate the behavior of
    manufacturer agents in response to regulatory prompts, systematically documenting
    each agent’s strategic decisions, adaptations, and overall performance [[35](https://arxiv.org/html/2411.15356v2#bib.bib35)].
    We examined how agents navigated regulatory challenges, interpreted new guidelines,
    and adjusted their product designs to meet evolving compliance requirements. The
    evaluation framework was modeled using a Benefit-Risk Ratio (BRR) assessment [[36](https://arxiv.org/html/2411.15356v2#bib.bib36)],
    inspired by FDA methodologies for evaluating product safety and effectiveness.
    At each time step, we calculated BRR values to assess whether agents met regulatory
    standards, analyzing their reasoning and adaptive strategies in response to regulatory
    pressure.
  id: totrans-32
  prefs: []
  type: TYPE_NORMAL
  zh: 我们的研究采用了大型语言模型（LLMs）来模拟制造商智能体对监管提示的反应，系统地记录每个智能体的战略决策、适应过程和整体表现[[35](https://arxiv.org/html/2411.15356v2#bib.bib35)]。我们研究了智能体如何应对监管挑战、解读新指南，并调整其产品设计以符合不断变化的合规要求。评估框架使用了效益-风险比（BRR）评估[[36](https://arxiv.org/html/2411.15356v2#bib.bib36)]，该方法灵感来源于FDA评估产品安全性和有效性的方法论。在每个时间步，我们计算BRR值以评估智能体是否符合监管标准，分析它们的推理过程和对监管压力的适应策略。
- en: The BRR calculation begins by extracting essential scores from each manufacturer
    agent’s submission. These include a safety score, an effectiveness score, and
    a compliance score, each rated on a scale from 1 to 10\. The compliance score
    is derived directly from the agent’s decision rating, which reflects the extent
    to which the product aligns with regulatory guidelines. To compute the overall
    benefit, the model sums the safety, effectiveness, and compliance scores, representing
    a holistic measure of the product’s positive impact. The risk component, represented
    by the adverse event score, quantifies potential negative outcomes associated
    with the product. The BRR is then calculated as the ratio of the aggregated benefit
    to the adverse event score, providing a comprehensive metric for regulatory evaluation.
    The final decision on whether to approve or reject a submission is determined
    by comparing the calculated BRR with a predefined approval threshold. If the BRR
    meets or exceeds this threshold, the product is deemed acceptable and receives
    approval. Conversely, if the BRR falls below the threshold, the submission is
    rejected. This structured approach allows the model to simulate real-world regulatory
    processes, similar to those employed by agencies such as the FDA, and ensures
    that the assessment balances safety, efficacy, and regulatory compliance in a
    robust and replicable manner[[36](https://arxiv.org/html/2411.15356v2#bib.bib36)].
  id: totrans-33
  prefs: []
  type: TYPE_NORMAL
  zh: BRR计算首先从每个制造商代理的提交中提取关键评分。这些评分包括安全评分、有效性评分和合规评分，每个评分都在1到10的范围内评定。合规评分直接来源于代理的决策评分，反映了产品与监管指导方针的一致程度。为了计算总体效益，模型将安全评分、有效性评分和合规评分相加，代表产品的整体积极影响。风险组件通过不良事件评分量化与产品相关的潜在负面结果。接着，BRR通过将汇总的效益与不良事件评分的比率进行计算，提供一个全面的监管评估指标。最终是否批准或拒绝提交的决定由计算出的BRR与预定的批准阈值进行比较。如果BRR达到或超过该阈值，产品被认为是可接受的并获得批准。相反，如果BRR低于阈值，提交将被拒绝。这种结构化的方法使得模型能够模拟现实世界中的监管过程，类似于FDA等机构采用的流程，并确保评估在安全性、有效性和合规性方面保持平衡，且具有强健性和可重复性[[36](https://arxiv.org/html/2411.15356v2#bib.bib36)]。
- en: 'We developed a comprehensive simulation environment comprising 10 distinct
    manufacturer agents and one regulatory agent, designed to emulate a dynamic regulatory
    ecosystem. The regulatory agent issued new guidelines, prompting the manufacturer
    agents to adapt and respond strategically. We created a set of 10 regulations—5
    strict and 5 lenient—and exposed agents to strict regulations for 10 time steps,
    followed by lenient regulations for 5 time steps, recording their responses throughout,
    as shown in Figure [1](https://arxiv.org/html/2411.15356v2#S3.F1 "Figure 1 ‣ 3
    Methodology ‣ Regulator-Manufacturer AI Agents Modeling: Mathematical Feedback-Driven
    Multi-Agent LLM Framework").'
  id: totrans-34
  prefs: []
  type: TYPE_NORMAL
  zh: '我们开发了一个综合模拟环境，包含10个不同的制造商代理和一个监管代理，旨在模拟一个动态的监管生态系统。监管代理发布新的指导方针，促使制造商代理进行战略性调整和回应。我们制定了一套10条法规——5条严格的法规和5条宽松的法规——并让代理在10个时间步骤内接触严格的法规，接着在5个时间步骤内接触宽松的法规，并在整个过程中记录它们的反应，如图[1](https://arxiv.org/html/2411.15356v2#S3.F1
    "Figure 1 ‣ 3 Methodology ‣ Regulator-Manufacturer AI Agents Modeling: Mathematical
    Feedback-Driven Multi-Agent LLM Framework")所示。'
- en: 'Agents were required to make decisions based on several factors, including
    the regulatory environment, financial resources, AI strategies, and plans for
    market adaptation. They also had to determine which products they could feasibly
    develop under these conditions. These decisions were then evaluated by the regulatory
    agent, using a risk-benefit ratio calculator to determine compliance. The calculator
    integrated metrics such as safety, effectiveness, and compliance, providing a
    quantitative framework for decision-making. Each metric, scored from 1 to 10,
    was aggregated to calculate the benefit, which was then divided by the adverse
    event score to yield the BRR. A submission was approved if the BRR met or exceeded
    a predefined threshold; otherwise, it was rejected. This approach ensured a systematic,
    balanced assessment of safety, efficacy, and regulatory adherence, reflecting
    real-world practices as shown in Figure [2](https://arxiv.org/html/2411.15356v2#S3.F2
    "Figure 2 ‣ 3 Methodology ‣ Regulator-Manufacturer AI Agents Modeling: Mathematical
    Feedback-Driven Multi-Agent LLM Framework").'
  id: totrans-35
  prefs: []
  type: TYPE_NORMAL
  zh: 代理人需要根据多个因素做出决策，包括监管环境、财务资源、AI策略以及市场适应计划。他们还必须确定在这些条件下可行的产品开发方向。然后，监管代理会使用风险收益比计算器评估这些决策，以确定是否合规。该计算器集成了安全性、有效性和合规性等指标，为决策提供了量化框架。每个指标都按1到10的评分进行评估，所有评分将汇总计算出收益，然后用不良事件得分除以该收益，以得出BRR。如果BRR达到或超过预定的阈值，则提交申请会被批准；否则，会被拒绝。这种方法确保了对安全性、有效性和监管合规性的系统性、平衡的评估，反映了如图[2](https://arxiv.org/html/2411.15356v2#S3.F2
    "图 2 ‣ 3 方法 ‣ 监管者-制造商 AI 代理建模：基于数学反馈驱动的多代理大语言模型框架")所示的现实世界实践。
- en: The simulation embedded regulatory knowledge and mathematical frameworks within
    the agents’ decision-making processes, guiding even those without a comprehensive
    understanding of device regulation to make informed choices. By modeling these
    interactions through nonlinear differential equations, we gained insights into
    how regulatory pressures influence compliance and innovation in the AI medical
    device sector. This approach allowed us to capture the complex dynamics between
    regulatory guidance and market responses, providing a detailed analysis of adaptive
    behaviors over time.
  id: totrans-36
  prefs: []
  type: TYPE_NORMAL
  zh: 模拟将监管知识和数学框架嵌入到代理人的决策过程中，甚至能够引导那些对设备监管没有全面了解的人做出明智的选择。通过通过非线性微分方程建模这些互动，我们深入了解了监管压力如何影响AI医疗设备领域的合规性和创新。这种方法使我们能够捕捉监管指导与市场反应之间的复杂动态，提供了对适应性行为随时间变化的详细分析。
- en: '![Refer to caption](img/8ef3d40f4dec924cfb4d3467873a836a.png)'
  id: totrans-37
  prefs: []
  type: TYPE_IMG
  zh: '![请参见说明](img/8ef3d40f4dec924cfb4d3467873a836a.png)'
- en: 'Figure 1: Interaction Between Regulatory Authority and Manufacturers Agents
    in Approval Processes'
  id: totrans-38
  prefs: []
  type: TYPE_NORMAL
  zh: 图 1：监管机构与制造商代理在审批过程中的互动
- en: '![Refer to caption](img/d40c1019cf750ebce3b7eb507c291f09.png)'
  id: totrans-39
  prefs: []
  type: TYPE_IMG
  zh: '![请参见说明](img/d40c1019cf750ebce3b7eb507c291f09.png)'
- en: 'Figure 2: Agent-Based Simulation of Pharmaceutical Regulatory Review Process'
  id: totrans-40
  prefs: []
  type: TYPE_NORMAL
  zh: 图 2：基于代理的制药监管审查过程模拟
- en: 3.1 Model Framework and Initialization
  id: totrans-41
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 3.1 模型框架和初始化
- en: Our experiment is built upon a two-layer design framework, integrating both
    mathematical modeling and multi-agent LLM simulations to rigorously investigate
    the interplay between regulatory guidance and manufacturer behavior. The first
    layer of this design involves constructing a set of transcendental equations that
    form the core of a realistic physical world model. We developed four key equations
    to describe the process by which a regulatory authority, such as a pharmaceutical
    or medical device regulatory body, issues guidance and how manufacturer agents
    adapt to this evolving regulatory environment. These equations capture the intricate
    feedback loops and adaptive behaviors that characterize real-world regulatory
    dynamics.
  id: totrans-42
  prefs: []
  type: TYPE_NORMAL
  zh: 我们的实验建立在一个双层设计框架之上，结合了数学建模和多代理大语言模型（LLM）模拟，严格研究了监管指导与制造商行为之间的相互作用。该设计的第一层涉及构建一组超越的方程，这些方程构成了一个现实物理世界模型的核心。我们开发了四个关键方程来描述监管机构（如制药或医疗器械监管机构）发布指导方针的过程，以及制造商代理如何适应这一不断变化的监管环境。这些方程捕捉了现实世界监管动态中复杂的反馈循环和适应性行为。
- en: The four main variables in this model are $G_{i}$, $C_{m}$, $M_{m}$, and $F_{m}$.
    Specifically, $G_{i}$ represents the guidance issuance rate, reflecting how quickly
    new regulatory requirements are introduced. $C_{m}$ denotes the compliance effort,
    a measure of the resources and actions manufacturers allocate to meet regulatory
    standards. $M_{m}$ stands for market adaptation, illustrating how well manufacturers
    adjust their strategies and operations in response to regulatory changes. Lastly,
    $F_{m}$ captures the feedback from manufacturers, representing the influence of
    collective industry responses on future regulatory decisions. Together, these
    equations simulate the complex interactions between regulatory authorities and
    manufacturers, offering a mathematically grounded view of compliance dynamics.
  id: totrans-43
  prefs: []
  type: TYPE_NORMAL
  zh: 本模型的四个主要变量是$G_{i}$、$C_{m}$、$M_{m}$和$F_{m}$。具体而言，$G_{i}$代表指导发布速率，反映了新监管要求被引入的速度。$C_{m}$表示合规努力，是衡量制造商为满足监管标准而分配的资源和行动的指标。$M_{m}$代表市场适应性，说明制造商在应对监管变化时调整战略和运营的能力。最后，$F_{m}$捕捉了制造商的反馈，代表行业集体反应对未来监管决策的影响。这些方程共同模拟了监管机构与制造商之间复杂的互动，提供了一个数学基础的合规动态视图。
- en: To ensure the equations accurately represent real-world scenarios, we apply
    a nonlinear least squares optimization method to determine initial values for
    the parameters, such as $alpha_{1}$, $phi_{1}$, $beta_{1}$, and others. This optimization
    aligns the model’s baseline state with either observed or theoretical expectations,
    providing a high-fidelity starting point for our simulations. Once we have these
    optimized parameters, we calculate the initial values for $G_{i}$, $C_{m}$, $M_{m}$,
    and $F_{m}$. These initial conditions set the stage for a realistic simulation,
    representing each agent’s starting point in terms of regulatory compliance and
    market positioning.
  id: totrans-44
  prefs: []
  type: TYPE_NORMAL
  zh: 为了确保方程式准确代表现实世界的情景，我们采用非线性最小二乘优化方法来确定参数的初始值，如$alpha_{1}$、$phi_{1}$、$beta_{1}$等。此优化将模型的基准状态与观察值或理论期望对齐，为我们的仿真提供一个高保真度的起始点。一旦我们获得了这些优化的参数，我们就可以计算$G_{i}$、$C_{m}$、$M_{m}$和$F_{m}$的初始值。这些初始条件为现实的仿真奠定了基础，代表每个代理在监管合规性和市场定位方面的起点。
- en: The second layer of our framework introduces multiple agents using large language
    models (LLMs) to simulate how manufacturer agents process regulatory guidance
    with Camel AI platform [[37](https://arxiv.org/html/2411.15356v2#bib.bib37)].
    Each agent reads and interprets regulatory documents through carefully crafted
    prompts, which simulate the decision-making process. Based on their understanding,
    the agents strategically adjust their internal parameters. For instance, an agent
    might increase $alpha_{1}$ to accelerate guidance issuance if the regulations
    demand stricter compliance, or they might adjust $phi_{2}$ to fine-tune their
    research and development investments in line with regulatory requirements. The
    reasoning behind each adjustment is recorded, providing a rich narrative that
    reveals the strategic thought processes of the agents.
  id: totrans-45
  prefs: []
  type: TYPE_NORMAL
  zh: 我们框架的第二层引入了多个使用大型语言模型（LLMs）的代理，模拟制造商代理如何通过 Camel AI 平台处理监管指导 [[37](https://arxiv.org/html/2411.15356v2#bib.bib37)]。每个代理通过精心设计的提示读取和解释监管文件，模拟决策过程。根据他们的理解，代理会战略性地调整内部参数。例如，如果法规要求更严格的合规性，某个代理可能会增加$alpha_{1}$以加速指导发布，或者他们可能会调整$phi_{2}$以根据监管要求微调其研发投资。每次调整背后的推理都会被记录下来，提供一个丰富的叙事，揭示代理的战略思维过程。
- en: A highlight of our approach is the dynamic interaction between the mathematical
    model and the LLM-based agents. After each agent makes its decisions and adjusts
    its parameters, these new values are fed back into the transcendental equations.
    The updated equations are then solved to calculate new values for $G_{i}$, $C_{m}$,
    $M_{m}$, and $F_{m}$. This iterative process creates a feedback loop where the
    mathematical model informs the LLM agents, and the agents’ decisions refine the
    mathematical outcomes. By grounding LLM decisions in a mathematical framework,
    we enhance the precision and realism of the simulations.
  id: totrans-46
  prefs: []
  type: TYPE_NORMAL
  zh: 我们方法的一大亮点是数学模型与基于LLM的代理之间的动态互动。每个代理做出决策并调整其参数后，这些新值会被反馈到超越方程中。然后求解更新后的方程，计算$G_{i}$、$C_{m}$、$M_{m}$和$F_{m}$的新值。这个迭代过程形成了一个反馈循环，数学模型为LLM代理提供信息，而代理的决策则精细化数学结果。通过将LLM决策嵌入数学框架中，我们提高了仿真的精确性和现实性。
- en: This integration ensures that the LLM agents’ strategic decisions are not only
    guided by linguistic understanding but are also validated and refined through
    rigorous mathematical calculations. As a result, the model becomes more robust,
    capturing the nuances of regulatory compliance and adaptation in a way that is
    both theoretically sound and practically relevant. This innovative combination
    of mathematical modeling and LLM simulations provides a comprehensive platform
    for exploring how manufacturers might respond to changing regulatory landscapes,
    offering insights into the effectiveness of different regulatory strategies.
  id: totrans-47
  prefs: []
  type: TYPE_NORMAL
  zh: 这种整合确保了LLM代理的战略决策不仅仅依赖于语言理解，还通过严格的数学计算进行验证和完善。因此，模型变得更加稳健，能够捕捉到监管合规性和适应性中的细微差别，以一种既理论上合理又实际相关的方式。这种数学建模与LLM模拟的创新结合，提供了一个全面的平台，用于探索制造商如何应对不断变化的监管环境，并为不同监管策略的有效性提供洞见。
- en: 'The experiment is grounded in a set of nonlinear differential equations that
    model key variables: Guidance Issuance Rate ($G_{i}$), Compliance Effort ($C_{m}$),
    Market Adaptation ($M_{m}$), and Manufacturer Feedback ($F_{m}$). The experiment
    proceeds as follows:'
  id: totrans-48
  prefs: []
  type: TYPE_NORMAL
  zh: 该实验基于一组非线性微分方程，这些方程模型化了关键变量：指导发布率（$G_{i}$）、合规努力（$C_{m}$）、市场适应性（$M_{m}$）和制造商反馈（$F_{m}$）。实验过程如下：
- en: 'Input: Initial state variables for each manufacturer agent; Total time steps
    $T$; System parametersOutput: Final state variables after simulationModule 1:
    InitializationInitialize manufacturer agents with different profiles, represented
    as:ManufacturerAgents = {10 instinct agents with each identity card}foreach *agent
    in ManufacturerAgents* do       Initialize agent’s state variables $G_{i}$, $C_{m}$,
    $M_{m}$       Assign agent.level based on corresponding profile characteristicsend
    foreachModule 2: Main Simulation Loopfor *$t\leftarrow 1$ to $T$* do       Step
    1: Regulatory agent issues new regulations       regulations $\leftarrow$ GenerateRegulations$(t)$      Step
    2: Manufacturers read regulations and prepare for compliance      foreach *agent
    in ManufacturerAgents* do             Read and interpret regulations       end
    foreach      Step 3: Manufacturers decide on compliance and update states      foreach *agent
    in ManufacturerAgents* do             3.1 Generate prompt reflecting agent level            
    prompt $\leftarrow$ GeneratePrompt(agent.level, regulations)            3.2 Agent
    uses decision model to decide on compliance             decision $\leftarrow$
    Decision(agent, prompt, model)            3.3 Update state variables based on
    decision             $G_{i}$, $C_{m}$, $M_{m}$, $F_{m}$ $\leftarrow$ UpdatePhysicalState(agent,
    decision, params)            3.4 Calculate compliance cost and market adaptation            
    cost, market_adaptation $\leftarrow$ CalculateCostAndAdaptation(agent, params)            3.5
    Agent submits compliance documents             if *decision == ”Comply”* then                  
    submission $\leftarrow$ PrepareSubmission(agent, regulations)                  
    BRR $\leftarrow$ CalculateBRR(submission)                   outcome $\leftarrow$
    EvaluateSubmission(BRR, approval_threshold)            3.6 Update agent’s state
    variables             agent.state $\leftarrow$ { $G_{i}$, $C_{m}$, $M_{m}$, $F_{m}$
    }             UpdateAgentState(agent, cost, market_adaptation)       end foreach      Step
    4: Regulatory agent reviews submissions and updates environment       feedback
    $\leftarrow$ CollectFeedback(submissions, outcomes)       UpdateEnvironment(feedback)      Step
    5: Record agents’ reactions and analyze results       RecordAndAnalyzeReactions(agent.states)end
    forModule 3: Output ResultsOutput all state variables and analysis results'
  id: totrans-49
  prefs: []
  type: TYPE_NORMAL
  zh: 输入：每个制造商代理的初始状态变量；总时间步数 $T$；系统参数输出：模拟后的最终状态变量模块 1：初始化初始化具有不同档案的制造商代理，表示为：ManufacturerAgents
    = {10 个具有身份卡的本能代理}对于 *ManufacturerAgents* 中的每个代理 执行       初始化代理的状态变量 $G_{i}$、$C_{m}$、$M_{m}$      
    根据相应档案特征分配代理.level结束 对于模块 2：主模拟循环对于 *$t\leftarrow 1$ 到 $T$* 执行       步骤 1：监管代理发布新法规      
    regulations $\leftarrow$ GenerateRegulations$(t)$      步骤 2：制造商读取法规并准备合规      对于 *ManufacturerAgents*
    中的每个代理 执行             阅读并解释法规       结束 对于      步骤 3：制造商决定是否合规并更新状态      对于 *ManufacturerAgents*
    中的每个代理 执行             3.1 生成反映代理级别的提示             prompt $\leftarrow$ GeneratePrompt(agent.level,
    regulations)            3.2 代理使用决策模型决定是否合规             decision $\leftarrow$ Decision(agent,
    prompt, model)            3.3 根据决策更新状态变量             $G_{i}$、$C_{m}$、$M_{m}$、$F_{m}$
    $\leftarrow$ UpdatePhysicalState(agent, decision, params)            3.4 计算合规成本和市场适应性            
    cost, market_adaptation $\leftarrow$ CalculateCostAndAdaptation(agent, params)            3.5
    代理提交合规文档             如果 *decision == ”Comply”* 则                   submission
    $\leftarrow$ PrepareSubmission(agent, regulations)                   BRR $\leftarrow$
    CalculateBRR(submission)                   outcome $\leftarrow$ EvaluateSubmission(BRR,
    approval_threshold)            3.6 更新代理的状态变量             agent.state $\leftarrow$
    { $G_{i}$、$C_{m}$、$M_{m}$、$F_{m}$ }             UpdateAgentState(agent, cost,
    market_adaptation)       结束 对于      步骤 4：监管代理审查提交并更新环境       feedback $\leftarrow$
    CollectFeedback(submissions, outcomes)       UpdateEnvironment(feedback)      步骤
    5：记录代理的反应并分析结果       RecordAndAnalyzeReactions(agent.states)结束 对于模块 3：输出结果输出所有状态变量和分析结果
- en: Our approach begins by optimizing the initial parameters ($\alpha_{1},\phi_{1},\beta_{1}$,
    etc.) through nonlinear least squares, ensuring a strong foundation for simulations.
    We then compute initial values for $G_{i},C_{m},M_{m},F_{m}$, establishing baseline
    states for each manufacturer agent. Agents interpret regulatory prompts, updating
    parameters based on strategic reasoning, such as adjusting compliance efforts
    or market adaptation. These updates are informed by a structured decision-making
    process and recalculated into new variable states. The simulation includes scenario-based
    role-playing, where agents adapt further as the narrative evolves, making strategic
    adjustments documented with rationale. We collect and visualize data at every
    step, mapping parameter changes and variable trends. This analysis highlights
    the impact of regulatory guidance and agent interactions, revealing patterns and
    strategic differences in compliance and market adaptation.
  id: totrans-50
  prefs: []
  type: TYPE_NORMAL
  zh: 我们的方法首先通过非线性最小二乘法优化初始参数（$\alpha_{1},\phi_{1},\beta_{1}$ 等），为仿真奠定坚实的基础。然后，我们计算$G_{i},C_{m},M_{m},F_{m}$的初始值，建立每个制造商代理的基准状态。代理根据监管提示进行解读，并基于战略推理更新参数，例如调整合规努力或市场适应。这些更新通过结构化的决策过程进行，并重新计算成新的变量状态。仿真包括基于场景的角色扮演，代理在故事情节发展的过程中进一步适应，做出战略调整并记录其理由。我们在每个步骤收集并可视化数据，绘制参数变化和变量趋势图。这一分析揭示了监管指导和代理互动的影响，揭示了合规和市场适应方面的模式和战略差异。
- en: 3.2 1st Mathematical Layer
  id: totrans-51
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 3.2 第一个数学层次
- en: Our model conceptualizes the regulatory environment as an adaptive flow, similar
    to a river shaping the landscape it traverses. Regulatory releases act as “currents”
    that influence the behavior of manufacturers. Using principles of Multi-Agent
    Modeling (MAM), we simulate a continuous regulatory-reaction cycle where feedback
    and regulatory updates interact dynamically. The system of equations presented
    below captures how regulatory guidance and feedback shape compliance efforts and
    market adaptation over time.
  id: totrans-52
  prefs: []
  type: TYPE_NORMAL
  zh: 我们的模型将监管环境概念化为一种适应性流动，类似于一条河流塑造其经过的景观。监管发布像是“水流”，影响制造商的行为。运用多代理建模（MAM）原理，我们模拟了一个持续的监管反应循环，在这个循环中，反馈和监管更新动态交互。以下方程组展示了监管指导和反馈如何随着时间的推移塑造合规努力和市场适应。
- en: '|  | $\displaystyle\frac{dG_{i}(t)}{dt}$ | $\displaystyle=\alpha_{1}\cdot(1-e^{-\phi_{1}\cdot
    t})-\beta_{1}\cdot F_{m}(t)$ |  | (1) |'
  id: totrans-53
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle\frac{dG_{i}(t)}{dt}$ | $\displaystyle=\alpha_{1}\cdot(1-e^{-\phi_{1}\cdot
    t})-\beta_{1}\cdot F_{m}(t)$ |  | (1) |'
- en: '|  | $\displaystyle\frac{dC_{m}(t)}{dt}$ | $\displaystyle=\alpha_{2}\cdot G_{i}(t)\cdot\left(1-e^{-\phi_{2}\cdot
    C_{m}(t)}% \right)-\beta_{2}\cdot\left(\frac{C_{m}(t)}{1+\gamma_{1}\cdot M_{m}(t)}\right)$
    |  | (2) |'
  id: totrans-54
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle\frac{dC_{m}(t)}{dt}$ | $\displaystyle=\alpha_{2}\cdot G_{i}(t)\cdot\left(1-e^{-\phi_{2}\cdot
    C_{m}(t)}\right)-\beta_{2}\cdot\left(\frac{C_{m}(t)}{1+\gamma_{1}\cdot M_{m}(t)}\right)$
    |  | (2) |'
- en: '|  | $\displaystyle\frac{dM_{m}(t)}{dt}$ | $\displaystyle=\alpha_{3}\cdot C_{m}(t)\cdot\left(1-e^{-\phi_{3}\cdot
    G_{i}(t)}% \right)-\beta_{3}\cdot M_{m}(t)$ |  | (3) |'
  id: totrans-55
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle\frac{dM_{m}(t)}{dt}$ | $\displaystyle=\alpha_{3}\cdot C_{m}(t)\cdot\left(1-e^{-\phi_{3}\cdot
    G_{i}(t)}\right)-\beta_{3}\cdot M_{m}(t)$ |  | (3) |'
- en: '|  | $\displaystyle F_{m}(t)$ | $\displaystyle=\alpha_{4}\cdot\left(\frac{M_{m}(t)\cdot\left(1-e^{-\phi_{4}%
    \cdot C_{m}(t)}\right)}{1+\gamma_{2}\cdot C_{m}(t)}\right)$ |  | (4) |'
  id: totrans-56
  prefs: []
  type: TYPE_TB
  zh: '|  | $\displaystyle F_{m}(t)$ | $\displaystyle=\alpha_{4}\cdot\left(\frac{M_{m}(t)\cdot\left(1-e^{-\phi_{4}\cdot
    C_{m}(t)}\right)}{1+\gamma_{2}\cdot C_{m}(t)}\right)$ |  | (4) |'
- en: The equation for the rate of guidance issuance, $\frac{dG_{i}(t)}{dt}$, reflects
    a balance between natural growth and inhibitory feedback. The term $\alpha_{1}\cdot(1-e^{-\phi_{1}\cdot
    t})$ models an initial rapid increase in guidance issuance that slows over time,
    akin to the Logistic Growth Model [[38](https://arxiv.org/html/2411.15356v2#bib.bib38)].
    The inhibitory term $-\beta_{1}\cdot F_{m}(t)$ aggregates feedback from manufacturers,
    aligning with systems dynamics principles where growth is moderated by systemic
    constraints [[39](https://arxiv.org/html/2411.15356v2#bib.bib39)].
  id: totrans-57
  prefs: []
  type: TYPE_NORMAL
  zh: 指导发布速率的方程$\frac{dG_{i}(t)}{dt}$反映了自然增长与抑制反馈之间的平衡。项$\alpha_{1}\cdot(1-e^{-\phi_{1}\cdot
    t})$模拟了指导发布的初期快速增长，随后随着时间推移减缓，类似于物流增长模型[[38](https://arxiv.org/html/2411.15356v2#bib.bib38)]。抑制项$-\beta_{1}\cdot
    F_{m}(t)$则聚合了来自制造商的反馈，符合系统动态原理，在这些原理中，增长受到系统约束的调节[[39](https://arxiv.org/html/2411.15356v2#bib.bib39)]。
- en: Compliance efforts, $\frac{dC_{m}(t)}{dt}$, are driven by the influence of guidance
    issuance and market adaptation. The term $\alpha_{2}\cdot G_{i}(t)\cdot\left(1-e^{-\phi_{2}\cdot
    C_{m}(t)}\right)$ quantifies how compliance scales with guidance, akin to innovation
    diffusion models [[40](https://arxiv.org/html/2411.15356v2#bib.bib40)]. Constraints
    are modeled by $-\beta_{2}\cdot\left(\frac{C_{m}(t)}{1+\gamma_{1}\cdot M_{m}(t)}\right)$,
    capturing the diminishing returns on compliance as market adaptation grows [[41](https://arxiv.org/html/2411.15356v2#bib.bib41)].
  id: totrans-58
  prefs: []
  type: TYPE_NORMAL
  zh: 合规努力，$\frac{dC_{m}(t)}{dt}$，受到指导发布和市场适应性影响。项$\alpha_{2}\cdot G_{i}(t)\cdot\left(1-e^{-\phi_{2}\cdot
    C_{m}(t)}\right)$量化了合规与指导之间的关系，类似于创新扩散模型[[40](https://arxiv.org/html/2411.15356v2#bib.bib40)]。约束条件由$-\beta_{2}\cdot\left(\frac{C_{m}(t)}{1+\gamma_{1}\cdot
    M_{m}(t)}\right)$建模，捕捉随着市场适应性增加，合规的递减效应[[41](https://arxiv.org/html/2411.15356v2#bib.bib41)]。
- en: Market adaptation, $\frac{dM_{m}(t)}{dt}$, depends on compliance efforts and
    guidance issuance. The compounding effect is captured by $\alpha_{3}\cdot C_{m}(t)\cdot\left(1-e^{-\phi_{3}\cdot
    G_{i}(t)}\right)$, which slows as saturation occurs, modeled by $-\beta_{3}\cdot
    M_{m}(t)$ [[39](https://arxiv.org/html/2411.15356v2#bib.bib39)].
  id: totrans-59
  prefs: []
  type: TYPE_NORMAL
  zh: 市场适应性，$\frac{dM_{m}(t)}{dt}$，依赖于合规努力和指导发布。复合效应由$\alpha_{3}\cdot C_{m}(t)\cdot\left(1-e^{-\phi_{3}\cdot
    G_{i}(t)}\right)$捕捉，随着饱和的发生而减缓，由$-\beta_{3}\cdot M_{m}(t)$建模[[39](https://arxiv.org/html/2411.15356v2#bib.bib39)]。
- en: The feedback factor $F_{m}(t)$ is modeled as $\alpha_{4}\cdot\left(\frac{M_{m}(t)\cdot\left(1-e^{-\phi_{4}\cdot
    C_{m}(t)}% \right)}{1+\gamma_{2}\cdot C_{m}(t)}\right)$, representing how market
    adaptation and compliance efforts influence feedback, incorporating diminishing
    returns [[42](https://arxiv.org/html/2411.15356v2#bib.bib42)].
  id: totrans-60
  prefs: []
  type: TYPE_NORMAL
  zh: 反馈因子$F_{m}(t)$被建模为$\alpha_{4}\cdot\left(\frac{M_{m}(t)\cdot\left(1-e^{-\phi_{4}\cdot
    C_{m}(t)}\right)}{1+\gamma_{2}\cdot C_{m}(t)}\right)$，代表市场适应性和合规努力如何影响反馈，结合了递减效应[[42](https://arxiv.org/html/2411.15356v2#bib.bib42)]。
- en: This mathematical framework captures the complex interplay between regulatory
    guidance, compliance dynamics, and feedback effects, providing a structured approach
    to modeling regulatory compliance and market adaptation.
  id: totrans-61
  prefs: []
  type: TYPE_NORMAL
  zh: 这一数学框架捕捉了监管指导、合规动态与反馈效应之间的复杂相互作用，为建模监管合规性和市场适应性提供了结构化的方法。
- en: Interdependencies and System Dynamics
  id: totrans-62
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 相互依赖关系与系统动态
- en: The interdependencies in our model illustrate the regulatory system’s complexity,
    emphasizing the interconnected nature of feedback, compliance, and market adaptation.
  id: totrans-63
  prefs: []
  type: TYPE_NORMAL
  zh: 我们模型中的相互依赖关系展示了监管系统的复杂性，强调了反馈、合规和市场适应性之间的相互联系。
- en: •
  id: totrans-64
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: Feedback ($F_{m}(t)$) directly influences the Guidance Issuance Rate ($G_{i}(t)$)
    through the inhibitory term $-\beta_{1}\cdot F_{m}(t)$, modulating the speed at
    which new regulatory guidance is issued.
  id: totrans-65
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 反馈（$F_{m}(t)$）通过抑制项$-\beta_{1}\cdot F_{m}(t)$直接影响指导发布率（$G_{i}(t)$），调节新监管指导发布的速度。
- en: •
  id: totrans-66
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: Guidance Issuance Rate ($G_{i}(t)$) impacts Compliance Efforts ($C_{m}(t)$)
    via the term $\alpha_{2}\cdot G_{i}(t)\cdot\left(1-e^{-\phi_{2}\cdot C_{m}(t)}\right)$,
    driving manufacturers to allocate resources toward meeting regulatory standards.
  id: totrans-67
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 指导发布率（$G_{i}(t)$）通过项$\alpha_{2}\cdot G_{i}(t)\cdot\left(1-e^{-\phi_{2}\cdot
    C_{m}(t)}\right)$影响合规努力（$C_{m}(t)$），驱动制造商将资源分配到满足监管标准。
- en: •
  id: totrans-68
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: Compliance Efforts ($C_{m}(t)$) shape Market Adaptation ($M_{m}(t)$) through
    the term $\alpha_{3}\cdot C_{m}(t)\cdot\left(1-e^{-\phi_{3}\cdot G_{i}(t)}\right)$,
    facilitating strategic adjustments to maintain competitive positioning.
  id: totrans-69
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 合规努力（$C_{m}(t)$）通过项$\alpha_{3}\cdot C_{m}(t)\cdot\left(1-e^{-\phi_{3}\cdot G_{i}(t)}\right)$塑造市场适应性（$M_{m}(t)$），促进战略调整以保持竞争定位。
- en: •
  id: totrans-70
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: •
- en: Market Adaptation ($M_{m}(t)$) and Compliance Efforts ($C_{m}(t)$) collectively
    influence Feedback ($F_{m}(t)$) through $\alpha_{4}\cdot\left(\frac{M_{m}(t)\cdot\left(1-e^{-\phi_{4}\cdot
    C_{m}(t)}% \right)}{1+\gamma_{2}\cdot C_{m}(t)}\right)$, which reflects how market
    and compliance dynamics inform the regulatory environment.
  id: totrans-71
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
  zh: 市场适应性（$M_{m}(t)$）和合规努力（$C_{m}(t)$）共同通过$\alpha_{4}\cdot\left(\frac{M_{m}(t)\cdot\left(1-e^{-\phi_{4}\cdot
    C_{m}(t)}\right)}{1+\gamma_{2}\cdot C_{m}(t)}\right)$影响反馈（$F_{m}(t)$），反映了市场和合规动态如何影响监管环境。
- en: '![Refer to caption](img/66eb91dcd89846aee177df2e705459e3.png)'
  id: totrans-72
  prefs: []
  type: TYPE_IMG
  zh: '![请参阅图例](img/66eb91dcd89846aee177df2e705459e3.png)'
- en: 'Figure 3: Diagram of interdependencies among variables, illustrating the regulatory
    feedback loop.'
  id: totrans-73
  prefs: []
  type: TYPE_NORMAL
  zh: 图 3：变量之间相互依赖关系的示意图，展示了监管反馈回路。
- en: 'The model depicts a cohesive regulatory flow: Feedback from manufacturers influences
    the Guidance Issuance Rate, which determines how rapidly new regulations are introduced.
    This rate subsequently drives Compliance Efforts, compelling manufacturers to
    align with regulatory expectations. Compliance Efforts, in turn, catalyze Market
    Adaptation, enabling strategic adjustments to maintain relevance. Finally, Market
    Adaptation and Compliance Efforts shape the Feedback mechanism, which informs
    future regulatory strategies, closing the adaptive loop.'
  id: totrans-74
  prefs: []
  type: TYPE_NORMAL
  zh: 模型展示了一个连贯的监管流程：制造商的反馈影响指导发布率，该发布率决定了新法规引入的速度。此发布率随后驱动合规努力，迫使制造商与监管期望保持一致。合规努力反过来催化市场适应，使战略调整能够保持相关性。最终，市场适应和合规努力共同塑造了反馈机制，进而指导未来的监管策略，闭合适应性循环。
- en: 3.3 2nd Agents Role Play
  id: totrans-75
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 3.3 第二代理角色扮演
- en: Regulatory Bodies These agents represent regulatory authorities responsible
    for issuing guidance documents, updating standards, and overseeing compliance.
    Operating on a cyclical basis, regulatory bodies periodically release new guidelines
    to reflect the changing landscape of medical device standards, influenced by emerging
    technologies, public health data, and industry feedback. These updates act as
    ”currents” within the regulatory flow, driving adaptive responses from other agents.
  id: totrans-76
  prefs: []
  type: TYPE_NORMAL
  zh: 监管机构 这些代理代表了负责发布指导文件、更新标准和监督合规的监管机构。监管机构以周期性方式运作，定期发布新指南，以反映医疗器械标准的变化格局，这些变化受到新兴技术、公共健康数据和行业反馈的影响。这些更新作为监管流程中的“潮流”，推动其他代理作出适应性反应。
- en: Manufacturers These agents simulate medical device manufacturers, tasked with
    interpreting new guidelines, assessing compliance costs, and adjusting operational
    strategies to maintain market access. Each manufacturer agent is designed with
    adaptive algorithms that allow them to allocate resources efficiently, balance
    innovation with regulatory demands, and anticipate future changes. Their strategic
    adjustments in response to new regulations highlight the self-organizing nature
    of regulatory systems, where decentralized decisions result in industry-wide compliance
    patterns.
  id: totrans-77
  prefs: []
  type: TYPE_NORMAL
  zh: 制造商 这些代理模拟医疗器械制造商，负责解读新指南、评估合规成本，并调整运营策略以保持市场准入。每个制造商代理都设计了适应性算法，使他们能够有效分配资源，平衡创新与监管需求，并预测未来变化。他们在回应新法规时的战略调整突出了监管系统的自组织特性，其中去中心化的决策导致了行业范围内的合规模式。
- en: Competitors (Other Manufacturers) Competitors within the industry engage in
    adaptive strategies to maintain competitive positions while responding to regulatory
    changes. By monitoring regulatory developments and adapting their compliance approaches,
    they create an environment of continuous innovation and improvement. This inter-competitive
    dynamic reinforces the necessity for manufacturers to stay agile, balancing regulatory
    adherence with the need to maintain market share.
  id: totrans-78
  prefs: []
  type: TYPE_NORMAL
  zh: 行业竞争者（其他制造商）在行业内的竞争者采用适应性策略以保持竞争地位，同时响应监管变化。通过监控监管动态并调整合规方法，他们创造了一个持续创新和改进的环境。这种竞争间的动态强化了制造商保持灵活性的必要性，平衡了遵守监管与保持市场份额的需求。
- en: 3.4 Environmental Setup
  id: totrans-79
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 3.4 环境设置
- en: The simulation environment models the regulatory landscape as a dynamic flow,
    where guidance updates act like currents, continuously influencing and reshaping
    agent behaviors. Regulatory bodies release guidance documents at regular intervals,
    informed by compliance data and feedback from manufacturers and healthcare providers.
    This steady stream of regulatory information drives manufacturers to adapt their
    compliance strategies, ensuring they remain aligned with evolving standards. Feedback
    mechanisms play a crucial role, allowing manufacturers and healthcare providers
    to share insights and responses with regulatory authorities, which, in turn, shape
    future updates. This creates a continuous cycle where real-world experiences and
    regulatory guidance influence each other. Manufacturers must adapt by balancing
    their resource allocation and compliance efforts, mirroring the real-world challenges
    and ongoing evolution of the regulatory environment.
  id: totrans-80
  prefs: []
  type: TYPE_NORMAL
  zh: 模拟环境将监管领域建模为一个动态流，其中指导更新就像水流，不断影响并重塑代理行为。监管机构定期发布指导文件，依据来自制造商和医疗服务提供者的合规数据和反馈。这一持续不断的监管信息流推动制造商调整其合规策略，确保其与不断发展的标准保持一致。反馈机制在其中起着至关重要的作用，允许制造商和医疗服务提供者与监管机构共享见解和回应，这反过来又影响未来的更新。这创造了一个持续的循环，现实世界的经验与监管指导相互影响。制造商必须通过平衡资源分配和合规努力来适应这一变化，反映了监管环境的现实挑战和持续演变。
- en: 'We developed comprehensive profiles for our manufacturer agents, each with
    unique attributes to reflect real-world variability. As illustrated in Figure
    [4](https://arxiv.org/html/2411.15356v2#S3.F4 "Figure 4 ‣ 3.4 Environmental Setup
    ‣ 3 Methodology ‣ Regulator-Manufacturer AI Agents Modeling: Mathematical Feedback-Driven
    Multi-Agent LLM Framework"), Company B, for instance, has a specific set of characteristics
    that influence its strategic decision-making. Across our simulation, all 10 agents
    are designed with distinct profiles, enabling nuanced interpretations and informed
    responses to regulatory requirements. To simulate regulatory challenges, we employed
    natural language processing (NLP) techniques to extract five critical topics from
    FDA regulatory texts pertaining to AI medical devices. We compiled these into
    a streamlined regulatory guide, abstracting complex guidelines into clear, actionable
    directives for agents to process efficiently. These scenarios were then deployed
    on the Camel AI platform, facilitating dynamic interactions among agents as they
    adapt to evolving regulatory landscapes.'
  id: totrans-81
  prefs: []
  type: TYPE_NORMAL
  zh: 我们为制造商代理开发了全面的档案，每个档案都具有独特的属性，以反映现实世界中的变异性。如图[4](https://arxiv.org/html/2411.15356v2#S3.F4
    "图 4 ‣ 3.4 环境设置 ‣ 3 方法论 ‣ 监管者-制造商 AI 代理建模：基于反馈驱动的多代理 LLM 框架")所示，例如，B 公司具有一套特定的特征，这些特征会影响其战略决策。在我们的模拟中，所有
    10 个代理都有各自独特的档案，使它们能够对监管要求作出细致的解读和回应。为了模拟监管挑战，我们使用自然语言处理（NLP）技术从 FDA 有关 AI 医疗器械的监管文本中提取了五个关键主题。我们将这些内容编纂成一本简明的监管指南，将复杂的指南抽象为清晰、可操作的指令，供代理高效处理。这些场景随后被部署到
    Camel AI 平台上，促使代理在应对不断变化的监管环境时进行动态交互。
- en: The Camel AI environment supports parallel execution of agents, adaptive feedback
    mechanisms, and dynamic corpora adjustments to reflect evolving regulatory content
    complexity. All experiments are run on a standard computational server equipped
    with 32GB RAM and NVIDIA GTX 1080 Ti GPUs. This configuration ensures efficient
    simulation of complex interactions and supports multiple agent interactions within
    a single execution cycle.
  id: totrans-82
  prefs: []
  type: TYPE_NORMAL
  zh: Camel AI 环境支持代理的并行执行、适应性反馈机制以及动态语料库调整，以反映不断变化的监管内容复杂性。所有实验均在配备 32GB 内存和 NVIDIA
    GTX 1080 Ti GPU 的标准计算服务器上运行。此配置确保了复杂交互的高效模拟，并支持在单一执行周期内多个代理的交互。
- en: '![Refer to caption](img/693ace17afc2606fef02a19a84e796fe.png)'
  id: totrans-83
  prefs: []
  type: TYPE_IMG
  zh: '![请参阅标题](img/693ace17afc2606fef02a19a84e796fe.png)'
- en: 'Figure 4: Prompts Example'
  id: totrans-84
  prefs: []
  type: TYPE_NORMAL
  zh: 图 4：提示示例
- en: Initial Parameter Estimation using Nonlinear Least Squares
  id: totrans-85
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 非线性最小二乘法的初步参数估计
- en: The optimization process was carried out using scipy.optimize.minimize in Python,
    employing a nonlinear least squares approach to iteratively refine parameter estimates
    [[43](https://arxiv.org/html/2411.15356v2#bib.bib43)]. Initial guesses for each
    parameter were assigned based on preliminary analysis to establish a starting
    point. The system of differential equations was integrated using odeint, generating
    model predictions for each variable over the simulation timeline. Parameters were
    adjusted in each iteration to minimize the objective function, defined as the
    sum of squared errors between model predictions and observed data for $G_{i}(t)$,
    $C_{m}(t)$, $M_{m}(t)$, and $F_{m}^{j}(t)$ at each time step. The optimization
    aimed to achieve a minimal objective function value, ensuring a close fit between
    model outputs and the observed data. Further model validation, including residual
    analysis and sensitivity testing, was planned to assess the robustness and reliability
    of the estimated parameters.
  id: totrans-86
  prefs: []
  type: TYPE_NORMAL
  zh: 优化过程在 Python 中使用 scipy.optimize.minimize 完成，采用非线性最小二乘法方法，通过迭代优化参数估计[[43](https://arxiv.org/html/2411.15356v2#bib.bib43)]。每个参数的初步猜测是基于初步分析进行分配的，以建立起一个起始点。系统的微分方程组使用
    odeint 进行积分，生成每个变量在仿真时间线上的模型预测。每次迭代中调整参数，以最小化目标函数，该函数定义为每个时间步长中模型预测与观察数据之间的平方误差之和，涉及
    $G_{i}(t)$、$C_{m}(t)$、$M_{m}(t)$ 和 $F_{m}^{j}(t)$。优化的目标是实现目标函数值的最小化，确保模型输出与观察数据之间的拟合度尽可能接近。进一步的模型验证，包括残差分析和敏感性测试，计划用来评估估计参数的鲁棒性和可靠性。
- en: To estimate these parameters, we defined an objective function that minimizes
    the sum of squared errors between model predictions and observed data across all
    four variables. For each time point $t$, the observed data for $G_{i}(t)$, $C_{m}(t)$,
    $M_{m}(t)$, and $F_{m}^{j}(t)$ was compared to model predictions generated by
    solving the differential equations with the given parameters.
  id: totrans-87
  prefs: []
  type: TYPE_NORMAL
  zh: 为了估计这些参数，我们定义了一个目标函数，最小化模型预测与观察数据之间的平方误差和，涵盖所有四个变量。对于每个时间点 $t$，观察到的数据 $G_{i}(t)$、$C_{m}(t)$、$M_{m}(t)$
    和 $F_{m}^{j}(t)$ 会与通过给定参数求解微分方程所生成的模型预测进行比较。
- en: 'The objective function was defined as:'
  id: totrans-88
  prefs: []
  type: TYPE_NORMAL
  zh: 目标函数定义如下：
- en: '|  | $\text{Objective}=\sum_{t}\left(E_{G}(t)+E_{C}(t)+E_{M}(t)+E_{F}(t)\right)$
    |  |'
  id: totrans-89
  prefs: []
  type: TYPE_TB
  zh: '|  | $\text{Objective}=\sum_{t}\left(E_{G}(t)+E_{C}(t)+E_{M}(t)+E_{F}(t)\right)$
    |  |'
- en: '|  | $E_{G}(t)=\left(G_{i}(t)_{\text{observed}}-G_{i}(t)_{\text{predicted}}\right)^{2}$
    |  |'
  id: totrans-90
  prefs: []
  type: TYPE_TB
  zh: '|  | $E_{G}(t)=\left(G_{i}(t)_{\text{observed}}-G_{i}(t)_{\text{predicted}}\right)^{2}$
    |  |'
- en: '|  | $E_{C}(t)=\left(C_{m}(t)_{\text{observed}}-C_{m}(t)_{\text{predicted}}\right)^{2}$
    |  |'
  id: totrans-91
  prefs: []
  type: TYPE_TB
  zh: '|  | $E_{C}(t)=\left(C_{m}(t)_{\text{observed}}-C_{m}(t)_{\text{predicted}}\right)^{2}$
    |  |'
- en: '|  | $E_{M}(t)=\left(M_{m}(t)_{\text{observed}}-M_{m}(t)_{\text{predicted}}\right)^{2}$
    |  |'
  id: totrans-92
  prefs: []
  type: TYPE_TB
  zh: '|  | $E_{M}(t)=\left(M_{m}(t)_{\text{observed}}-M_{m}(t)_{\text{predicted}}\right)^{2}$
    |  |'
- en: '|  | $E_{F}(t)=\left(F_{m}^{j}(t)_{\text{observed}}-F_{m}^{j}(t)_{\text{predicted}}%
    \right)^{2}$ |  |'
  id: totrans-93
  prefs: []
  type: TYPE_TB
  zh: '|  | $E_{F}(t)=\left(F_{m}^{j}(t)_{\text{observed}}-F_{m}^{j}(t)_{\text{predicted}}%
    \right)^{2}$ |  |'
- en: 3.5 Evaluation and Validation
  id: totrans-94
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 3.5 评估与验证
- en: In our study, we employed a comprehensive approach to assess the model’s performance
    and validate its reliability. Evaluation Metrics included metrics such as Guidance
    Adherence Accuracy and Compliance Stability, chosen for their relevance in measuring
    how effectively agents align with regulatory requirements and maintain steady
    compliance efforts. Guidance Adherence Accuracy quantifies the degree to which
    manufacturer agents’ compliance efforts match regulatory expectations over time,
    while Compliance Stability evaluates fluctuations in these efforts, reflecting
    the system’s ability to adapt smoothly to evolving regulations.
  id: totrans-95
  prefs: []
  type: TYPE_NORMAL
  zh: 在我们的研究中，我们采用了一种综合方法来评估模型的表现并验证其可靠性。评估指标包括指导一致性准确度和合规性稳定性等指标，这些指标因其在衡量代理如何有效地与监管要求对齐并保持稳定合规性方面的相关性而被选择。指导一致性准确度量化了制造商代理的合规努力在时间推移中与监管预期的匹配程度，而合规性稳定性评估了这些努力的波动，反映了系统在应对不断变化的监管要求时的适应能力。
- en: To ensure robustness, we applied validation techniques such as sensitivity analysis.
    By systematically varying model parameters, we examined the impacts on key parameters.
    This method allowed us to identify critical parameters that significantly influence
    model dynamics and to confirm that the model’s responses remain consistent and
    predictable under various scenarios. Additionally, the analysis revealed non-linear
    and asymmetric effects, demonstrating the model’s capability to capture complex
    interactions between regulatory guidance and market adaptation.
  id: totrans-96
  prefs: []
  type: TYPE_NORMAL
  zh: 为确保模型的鲁棒性，我们应用了验证技术，如敏感性分析。通过系统地变化模型参数，我们检查了关键参数的影响。该方法使我们能够识别出对模型动态有显著影响的关键参数，并确认在各种情境下，模型的响应保持一致且可预测。此外，分析还揭示了非线性和不对称的效应，展示了模型捕捉监管指导与市场适应之间复杂交互作用的能力。
- en: These measures collectively confirm that our model not only performs well on
    the test data but also adapts effectively to varying regulatory and market conditions.
    The combination of precise evaluation and thorough validation ensures that our
    approach can simulate realistic regulatory environments and agent behaviors with
    a high degree of reliability. Future work will further enhance this analysis by
    incorporating real-world data for empirical validation and exploring advanced
    sensitivity analysis technique.
  id: totrans-97
  prefs: []
  type: TYPE_NORMAL
  zh: 这些措施共同确认了我们的模型不仅在测试数据上表现良好，而且能够有效适应不断变化的监管和市场条件。精确的评估和充分的验证确保了我们的方法能够在高可靠性下模拟现实的监管环境和代理行为。未来的工作将通过引入真实世界的数据进行实证验证，并探索更先进的敏感性分析技术，进一步增强这一分析。
- en: Evaluation Metrics of Guidance Adherence Accuracy
  id: totrans-98
  prefs: []
  type: TYPE_NORMAL
  zh: 指导遵循准确性评估指标
- en: 'Guidance adherence measures the degree to which manufacturers align their compliance
    efforts with the issued guidance. We calculate this as the percentage of time
    steps in which compliance efforts closely match the recommended values derived
    from regulatory guidance. For each time step $t$, adherence is determined by comparing
    the calculated compliance effort $C_{m}(t)$ with expected effort benchmarks provided
    by the guidance issuance rate $G_{i}(t)$:'
  id: totrans-99
  prefs: []
  type: TYPE_NORMAL
  zh: 指导遵循度衡量制造商在多大程度上将其合规努力与发布的指导意见对齐。我们通过计算合规努力与监管指导所衍生的推荐值在每个时间步的匹配程度，来得出这一指标。对于每个时间步$t$，遵循度通过比较计算出的合规努力$C_{m}(t)$与由指导发布率$G_{i}(t)$提供的预期努力基准来确定：
- en: '|  | $\text{Adherence Accuracy}=\frac{1}{T}\sum_{t=1}^{T}\mathbb{1}\left(&#124;C_{m}(t)-G%
    _{i}(t)&#124;<\epsilon\right)$ |  |'
  id: totrans-100
  prefs: []
  type: TYPE_TB
  zh: '|  | $\text{遵循准确性}=\frac{1}{T}\sum_{t=1}^{T}\mathbb{1}\left(&#124;C_{m}(t)-G%
    _{i}(t)&#124;<\epsilon\right)$ |  |'
- en: where $T$ is the total number of time steps, and $epsilon$ is a threshold for
    acceptable deviation. This metric evaluates how effectively the model influences
    manufacturers to adopt behaviors in line with regulatory expectations.
  id: totrans-101
  prefs: []
  type: TYPE_NORMAL
  zh: 其中，$T$ 是总的时间步数，而$epsilon$是可接受偏差的阈值。该度量评估了模型如何有效地促使制造商采纳与监管期望一致的行为。
- en: Evaluation Metrics of Compliance Stability
  id: totrans-102
  prefs: []
  type: TYPE_NORMAL
  zh: 合规稳定性评估指标
- en: 'Compliance stability assesses fluctuations in compliance efforts $C_{m}(t)$
    over time, offering insight into the system’s resilience to regulatory updates.
    Lower variance in compliance efforts indicates a smoother adaptation to regulatory
    changes and reflects an agent’s ability to maintain steady compliance:'
  id: totrans-103
  prefs: []
  type: TYPE_NORMAL
  zh: 合规稳定性评估了合规努力$C_{m}(t)$随时间的波动，提供了关于系统对监管更新的弹性洞察。合规努力的较低方差表明更平稳的适应监管变化，并反映了代理维持稳定合规的能力：
- en: '|  | $\text{Compliance Stability}=\frac{1}{T}\sum_{t=1}^{T}\left(C_{m}(t)-\overline{%
    C_{m}}\right)^{2}$ |  |'
  id: totrans-104
  prefs: []
  type: TYPE_TB
  zh: '|  | $\text{合规稳定性}=\frac{1}{T}\sum_{t=1}^{T}\left(C_{m}(t)-\overline{% C_{m}}\right)^{2}$
    |  |'
- en: where $\overline{C_{m}}$ is the average compliance effort over $T$ time steps.
    A lower stability score reflects higher regulatory resilience, suggesting that
    agents respond consistently even with evolving regulatory requirements.
  id: totrans-105
  prefs: []
  type: TYPE_NORMAL
  zh: 其中，$\overline{C_{m}}$ 是$T$个时间步的平均合规努力。较低的稳定性得分反映了较高的监管弹性，表明即便监管要求不断变化，代理仍能保持一致的反应。
- en: These metrics collectively allow us to evaluate the regulatory flow model’s
    ability to simulate real-world adaptive behaviors under complex regulatory corpora,
    providing insight into regulatory effectiveness and agent adaptability in diverse
    compliance scenarios.
  id: totrans-106
  prefs: []
  type: TYPE_NORMAL
  zh: 这些指标共同使我们能够评估监管流模型在复杂监管体系下模拟现实世界适应行为的能力，为我们提供了关于监管有效性和代理适应性的深刻洞察，适用于多种合规场景。
- en: Sensitivity Analysis
  id: totrans-107
  prefs:
  - PREF_H4
  type: TYPE_NORMAL
  zh: 敏感性分析
- en: 'We systematically varied each model parameter across a range of values and
    observed the resulting changes in four key outputs: the Guidance Issuance Rate
    ($G_{i}$), Compliance Effort ($C_{m}$), Market Adaptation ($M_{m}$), and Manufacturer
    Feedback ($F_{m}$). The goal was to assess which parameters exert the most influence
    on system behavior and to validate the model’s structural soundness.'
  id: totrans-108
  prefs: []
  type: TYPE_NORMAL
  zh: 我们系统地改变了每个模型参数的值，并观察了四个关键输出的变化：指导发布率（$G_{i}$）、合规努力（$C_{m}$）、市场适应性（$M_{m}$）和制造商反馈（$F_{m}$）。目标是评估哪些参数对系统行为的影响最大，并验证模型的结构稳健性。
- en: 4 Results
  id: totrans-109
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 4 结果
- en: 4.1 Regulatory Response and Parameter Evolution of Manufacturer Agents
  id: totrans-110
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 4.1 制造商代理的监管响应与参数演变
- en: 'We conducted a series of experiments in which we subjected different manufacturer
    agents, to the same regulatory environment. Each agent was provided with identical
    regulatory guidelines to analyze and respond to. For instance, one of the regulations
    presented to the agents stated: ”Algorithm Transparency and Traceability: Manufacturers
    of AI-based medical devices must ensure comprehensive transparency of algorithmic
    processes. This includes the requirement to document and disclose the decision-making
    mechanisms at every stage of the model, particularly in complex architectures
    such as deep neural networks. The traceability of decisions made by the model
    must be established, providing a clear audit trail of how each layer contributes
    to the final outcome. This documentation should be structured to enable regulatory
    bodies to conduct in-depth assessments and identify specific points of failure
    or risk when necessary.” Upon reading and interpreting the regulations, the agents
    autonomously decided on strategies to comply, which resulted in adjustments to
    their operational parameters, such as $\alpha_{1},\alpha_{2},\beta_{1}$, and $\gamma_{1}$,
    over time as shown in Figure [5](https://arxiv.org/html/2411.15356v2#S4.F5 "Figure
    5 ‣ 4.1 Regulatory Response and Parameter Evolution of Manufacturer Agents ‣ 4
    Results ‣ Regulator-Manufacturer AI Agents Modeling: Mathematical Feedback-Driven
    Multi-Agent LLM Framework") and Figure [6](https://arxiv.org/html/2411.15356v2#S4.F6
    "Figure 6 ‣ 4.1 Regulatory Response and Parameter Evolution of Manufacturer Agents
    ‣ 4 Results ‣ Regulator-Manufacturer AI Agents Modeling: Mathematical Feedback-Driven
    Multi-Agent LLM Framework"). These parameter changes reflect the evolution of
    their strategies under the imposed regulatory constraints, as shown in the multi-panel
    visualization of parameter trajectories across companies (A–J).'
  id: totrans-111
  prefs: []
  type: TYPE_NORMAL
  zh: '我们进行了一系列实验，将不同制造商的代理暴露在相同的监管环境中。每个代理都提供了相同的监管指南，以供分析和响应。例如，其中一项呈现给代理的法规指出：“算法透明性和可追溯性：基于人工智能的医疗设备制造商必须确保算法过程的全面透明。这包括要求在每个模型阶段，特别是在深度神经网络等复杂架构中，记录和披露决策机制。模型所做决策的可追溯性必须得到建立，提供清晰的审计轨迹，说明每一层如何影响最终结果。该文档应以结构化的方式呈现，以便监管机构能够进行深入评估，并在必要时识别具体的故障点或风险。”在阅读并解读这些法规后，代理自主决定了合规策略，并随着时间的推移对其操作参数（如$\alpha_{1},\alpha_{2},\beta_{1}$和$\gamma_{1}$）进行了调整，如图[5](https://arxiv.org/html/2411.15356v2#S4.F5
    "Figure 5 ‣ 4.1 Regulatory Response and Parameter Evolution of Manufacturer Agents
    ‣ 4 Results ‣ Regulator-Manufacturer AI Agents Modeling: Mathematical Feedback-Driven
    Multi-Agent LLM Framework")和图[6](https://arxiv.org/html/2411.15356v2#S4.F6 "Figure
    6 ‣ 4.1 Regulatory Response and Parameter Evolution of Manufacturer Agents ‣ 4
    Results ‣ Regulator-Manufacturer AI Agents Modeling: Mathematical Feedback-Driven
    Multi-Agent LLM Framework")所示。这些参数变化反映了在强加的监管约束下，它们策略的演变，正如公司之间的参数轨迹多面可视化（A–J）所展示的那样。'
- en: 'Figure [7](https://arxiv.org/html/2411.15356v2#S4.F7 "Figure 7 ‣ 4.1 Regulatory
    Response and Parameter Evolution of Manufacturer Agents ‣ 4 Results ‣ Regulator-Manufacturer
    AI Agents Modeling: Mathematical Feedback-Driven Multi-Agent LLM Framework") illustrates
    the temporal dynamics of four key metrics—Regulation Rate, Compliance Cost, Market
    Adaptability, and Manufacturer Feedback—across multiple companies (A–J) over a
    series of time steps. The regulation rate (top left) shows a steady and consistent
    increase across all companies, with some exhibiting faster growth trajectories,
    indicating variability in their ability to respond to regulatory pressures. Similarly,
    compliance cost (top right) follows an exponential growth pattern, with companies
    converging on comparable trajectories over time, reflecting a shared burden of
    regulatory adherence as the regulation rate increases. In contrast, market adaptability
    (bottom left) displays significant inter-company variability, with certain companies
    (e.g., B and D) exhibiting sharp peaks and fluctuations, likely reflecting strategic
    experimentation or dynamic market responses, while others maintain lower or more
    stable levels, suggesting resource constraints or differing strategies. Manufacturer
    feedback (bottom right) grows steadily across companies, with some (e.g., Company
    J) showing a notably sharper increase, highlighting varying levels of engagement
    with feedback mechanisms and their potential influence on compliance and adaptability
    strategies. Together, these metrics provide a comprehensive view of how companies
    balance regulatory compliance, cost, market adaptability, and external feedback
    under evolving regulatory environments.'
  id: totrans-112
  prefs: []
  type: TYPE_NORMAL
  zh: '图[7](https://arxiv.org/html/2411.15356v2#S4.F7 "Figure 7 ‣ 4.1 Regulatory Response
    and Parameter Evolution of Manufacturer Agents ‣ 4 Results ‣ Regulator-Manufacturer
    AI Agents Modeling: Mathematical Feedback-Driven Multi-Agent LLM Framework")展示了跨多个公司（A–J）在一系列时间步骤中的四个关键指标的时间动态——监管率、合规成本、市场适应性和制造商反馈。监管率（左上角）显示所有公司均呈现稳定且一致的增长，其中一些公司显示出更快的增长轨迹，表明它们在应对监管压力方面的能力存在差异。类似地，合规成本（右上角）呈指数增长模式，随着时间的推移，公司逐渐趋向相似的轨迹，反映出随着监管率增加，它们在遵守监管要求方面承受着共同的负担。相比之下，市场适应性（左下角）表现出显著的公司间差异，某些公司（例如B和D）展示出急剧的峰值和波动，可能反映了战略实验或动态市场反应，而其他公司则保持较低或更稳定的水平，表明可能存在资源限制或不同的战略。制造商反馈（右下角）在所有公司中稳步增长，部分公司（例如公司J）显示出明显更快的增长，突出了各公司在反馈机制中的参与度差异及其可能对合规性和适应性战略的影响。这些指标共同提供了一个全面的视角，展示了公司在不断变化的监管环境中如何平衡监管合规、成本、市场适应性和外部反馈。'
- en: '![Refer to caption](img/c857c80f4e4341a02e43b358042eb836.png)'
  id: totrans-113
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明文字](img/c857c80f4e4341a02e43b358042eb836.png)'
- en: 'Figure 5: Analysis of Parameter Change and Value Distribution'
  id: totrans-114
  prefs: []
  type: TYPE_NORMAL
  zh: 图5：参数变化和数值分布分析
- en: '![Refer to caption](img/688d906892376f4edb0dc7e10fe16247.png)'
  id: totrans-115
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明文字](img/688d906892376f4edb0dc7e10fe16247.png)'
- en: 'Figure 6: Figure: Analysis of Parameter Sensitivity and Value Distribution'
  id: totrans-116
  prefs: []
  type: TYPE_NORMAL
  zh: 图6：图：参数敏感性和数值分布分析
- en: '![Refer to caption](img/d2c082f8c94fef7ff07e7f5c9bf79bf2.png)'
  id: totrans-117
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明文字](img/d2c082f8c94fef7ff07e7f5c9bf79bf2.png)'
- en: 'Figure 7: Temporal Dynamics of Key Metrics Under Regulatory Pressure Across
    Companies'
  id: totrans-118
  prefs: []
  type: TYPE_NORMAL
  zh: 图7：公司在监管压力下关键指标的时间动态
- en: 'We can see upon exposure to the regulations, each agent processes the requirements
    and adapts its strategy by modifying internal parameters to achieve compliance
    while maintaining competitive efficiency. Initially, during the early time steps,
    most agents display a rapid upward adjustment in $\alpha_{1}$ and $\alpha_{2}$,
    reflecting a focused effort toward regulatory adherence. This phase is particularly
    evident in agents representing Companies A, B, and J, where stabilization occurs
    quickly, suggesting robust initial responses. In the middle time steps, divergence
    emerges as agents prioritize different strategies: some allocate resources to
    traceability ($\gamma_{1},\gamma_{2}$), while others focus on market adaptation
    ($\beta_{1},\beta_{2}$). By the later stages, many agents reach stabilization,
    balancing regulatory compliance and operational constraints, although some agents,
    such as those representing Companies C, G, and H, exhibit periodic fluctuations
    in $\gamma_{1}$ and $\gamma_{2}$, indicating ongoing refinements or challenges.
    Anomalies, such as the sudden drop in $\alpha_{2}$ for Company G or irregular
    spikes in $\gamma_{1}$ for Company D, suggest strategic failures or difficulties
    in meeting specific requirements, such as establishing audit trails for complex
    neural networks. These findings highlight the diverse strategies agents adopt,
    reflecting trade-offs between regulatory compliance and competitiveness.'
  id: totrans-119
  prefs: []
  type: TYPE_NORMAL
  zh: 我们可以看到，在暴露于法规后，每个代理人都会处理这些要求，并通过调整内部参数来适应其策略，以实现合规，同时保持竞争效率。最初，在早期的时间步骤中，大多数代理人表现出$\alpha_{1}$和$\alpha_{2}$的快速上升调整，反映出在法规遵守方面的集中努力。这个阶段在代表公司A、B和J的代理人中尤为明显，稳定化过程发生得很快，表明初步响应非常强劲。在中期时间步骤中，出现了分化，因为代理人优先采用不同的策略：一些代理人将资源分配给可追溯性（$\gamma_{1},\gamma_{2}$），而其他代理人则专注于市场适应性（$\beta_{1},\beta_{2}$）。到了后期，许多代理人达到了稳定状态，平衡了法规遵守和操作约束，尽管一些代理人，如代表公司C、G和H的代理人，表现出$\gamma_{1}$和$\gamma_{2}$的周期性波动，表明持续的优化或挑战。异常现象，如公司G的$\alpha_{2}$骤降，或公司D的$\gamma_{1}$不规则峰值，表明战略失败或在满足特定要求（例如为复杂神经网络建立审计追踪）时遇到困难。这些发现突出了代理人采用的多样化策略，反映了在法规遵守和竞争力之间的权衡。
- en: 4.2 Effect of Resource Constraints on Adaptive Strategies
  id: totrans-120
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 4.2 资源约束对适应性策略的影响
- en: 'This study examines the allocation of compliance resources by each company
    and its subsequent impact on market adaptability. Based on the results, companies
    are categorized into three distinct groups reflecting their resource levels: limited,
    medium, and rich. This categorization allows for a detailed analysis of how varying
    levels of resource investment influence the ability of companies to adapt to market
    demands within a regulated environment. The results are visualized using violin
    plots in Figure [8](https://arxiv.org/html/2411.15356v2#S4.F8 "Figure 8 ‣ 4.2
    Effect of Resource Constraints on Adaptive Strategies ‣ 4 Results ‣ Regulator-Manufacturer
    AI Agents Modeling: Mathematical Feedback-Driven Multi-Agent LLM Framework"),
    which are overlaid with summary statistics to display the distribution of market
    adaptability scores and provide insights into inter-company variability under
    each condition.'
  id: totrans-121
  prefs: []
  type: TYPE_NORMAL
  zh: 本研究探讨了各公司在合规资源配置上的差异及其对市场适应性的后续影响。根据结果，公司被分为三类，分别为资源有限型、资源中等型和资源丰富型。这一分类有助于详细分析不同资源投入水平如何影响公司在受监管环境下适应市场需求的能力。结果通过图
    [8](https://arxiv.org/html/2411.15356v2#S4.F8 "图 8 ‣ 4.2 资源约束对适应性策略的影响 ‣ 4 结果
    ‣ 监管者-制造商 AI 代理建模：数学反馈驱动的多代理 LLM 框架")中的小提琴图进行了可视化，并叠加了汇总统计数据，以显示市场适应性评分的分布，并提供关于各公司在不同条件下变异性的洞察。
- en: '![Refer to caption](img/68539064e86a205e98a76f49205e5351.png)'
  id: totrans-122
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明文字](img/68539064e86a205e98a76f49205e5351.png)'
- en: 'Figure 8: Resource Allocation and Market Adaptability Categorization Across
    Companies'
  id: totrans-123
  prefs: []
  type: TYPE_NORMAL
  zh: 图 8：跨公司资源配置与市场适应性分类
- en: Company C, D, H and I are categorized as resources_limited scenario, significant
    differences in market adaptability were observed among companies ($F(3,152.81)=5.76$,
    $p=9.23\times 10^{-4}$). Company H exhibited the highest mean adaptability ($\bar{x}=3167.47$),
    markedly outperforming its counterparts. The Bonferroni-adjusted $p$-value of
    0.03 further confirmed the robustness of these findings, while the variance explained
    by group differences ($\sigma_{B}^{2}=0.08$) indicates that approximately 8% of
    the variability in market adaptability can be attributed to differences among
    companies. This suggests that under conditions of resource scarcity, certain companies
    may be better equipped to adapt due to intrinsic factors such as efficiency, innovation,
    or strategic management.
  id: totrans-124
  prefs: []
  type: TYPE_NORMAL
  zh: 公司C、D、H和I被归类为资源有限的情境，观察到公司间市场适应性存在显著差异（$F(3,152.81)=5.76$, $p=9.23\times 10^{-4}$）。公司H表现出最高的平均适应性（$\bar{x}=3167.47$），显著优于其他公司。Bonferroni调整后的$p$值为0.03，进一步确认了这些发现的可靠性，而由组间差异解释的方差（$\sigma_{B}^{2}=0.08$）表明大约8%的市场适应性变异性可归因于公司之间的差异。这表明在资源匮乏的情况下，某些公司可能由于效率、创新或战略管理等内在因素，更能适应市场变化。
- en: The resources_medium scenario, Agent E, F, G, revealed no statistically significant
    differences in market adaptability among companies ($F(2,143.29)=0.35$, $p=0.71$).
    The mean adaptability scores across all companies were closely aligned, indicating
    that moderate levels of resources may result in homogenized performance. The explained
    variance was effectively negligible ($\sigma_{B}^{2}=0.00$), suggesting that adaptability
    under these conditions is largely independent of company-level factors. This observation
    highlights the stabilizing effects of balanced resource availability, which may
    reduce inter-company disparities.
  id: totrans-125
  prefs: []
  type: TYPE_NORMAL
  zh: 在资源中等的情境下，代理人E、F、G之间的公司市场适应性未表现出统计学上显著的差异（$F(2,143.29)=0.35$, $p=0.71$）。所有公司的平均适应性分数非常接近，表明适度的资源水平可能导致表现趋同。由组间差异解释的方差几乎可以忽略不计（$\sigma_{B}^{2}=0.00$），这表明在这种条件下，适应性在很大程度上不受公司层面因素的影响。此观察结果突显了平衡资源可用性的稳定效应，可能减少公司间的差异。
- en: The resources_rich scenario, Agent A, B and J, on the other hand, displayed
    pronounced differences in market adaptability across companies ($F(2,96.01)=84.96$,
    $p=5.77\times 10^{-22}$). Company A demonstrated an extraordinary mean adaptability
    score ($\bar{x}=9.71\times 10^{5}$), significantly exceeding the performance of
    other companies. The variance explained by group differences was substantial ($\sigma_{B}^{2}=0.63$),
    indicating that approximately 63% of the variability in market adaptability can
    be attributed to company identity under resource-rich conditions. The Bonferroni-adjusted
    $p$-values ($p<0.001$) confirmed the significance of these differences, reinforcing
    the notion that abundant resources magnify inter-company disparities, possibly
    by amplifying existing advantages in technology, infrastructure, or market reach.
  id: totrans-126
  prefs: []
  type: TYPE_NORMAL
  zh: 在资源丰富的情境下，代理人A、B和J之间的市场适应性差异明显（$F(2,96.01)=84.96$, $p=5.77\times 10^{-22}$）。公司A表现出异常高的平均适应性分数（$\bar{x}=9.71\times
    10^{5}$），显著超过了其他公司的表现。由组间差异解释的方差较大（$\sigma_{B}^{2}=0.63$），表明大约63%的市场适应性变异性可归因于公司身份在资源丰富的条件下。经过Bonferroni调整后的$p$值（$p<0.001$）确认了这些差异的显著性，进一步强化了这样一种观点：丰富的资源放大了公司间的差距，可能通过放大现有的技术、基础设施或市场覆盖优势。
- en: The findings illustrate a complex relationship between resource availability
    and market adaptability. Under limited resources, adaptability disparities are
    moderate but significant, likely driven by intrinsic company characteristics.
    Medium resource conditions neutralize these differences, suggesting a stabilizing
    effect of balanced resource allocation. However, resource abundance appears to
    exacerbate adaptability disparities, with certain companies achieving extraordinary
    levels of performance. These results underscore the importance of understanding
    how resource availability interacts with company-level factors to influence competitive
    dynamics and market success.
  id: totrans-127
  prefs: []
  type: TYPE_NORMAL
  zh: 研究结果揭示了资源可用性与市场适应性之间复杂的关系。在资源有限的情况下，适应性差异适中但显著，可能是由公司内在特征驱动的。中等资源条件下，这些差异被中和，表明平衡的资源分配具有稳定作用。然而，资源丰富似乎加剧了适应性差异，某些公司达到了异常的业绩水平。这些结果强调了理解资源可用性如何与公司层面的因素相互作用，从而影响竞争动态和市场成功的重要性。
- en: 'Figure [12](https://arxiv.org/html/2411.15356v2#S4.F12 "Figure 12 ‣ 4.4 Module
    evaluation and sensitivity result ‣ 4 Results ‣ Regulator-Manufacturer AI Agents
    Modeling: Mathematical Feedback-Driven Multi-Agent LLM Framework") illustrates
    the market adaptability achieved by each company after 73 time steps, highlighting
    the outcomes of their strategic decisions and compliance resource allocations.
    The vertical axis represents market adaptability, while the horizontal axis categorizes
    companies (A–J). Companies within the resources_rich category (e.g., A, B, and
    J) consistently achieve the highest adaptability scores, underscoring the advantages
    of abundant resources in fostering strategic flexibility and responsiveness to
    market dynamics. In contrast, companies categorized as resources_limited (e.g.,
    C, D, H, and I) exhibit significantly lower adaptability, with notable variability
    among them. Notably, Company H outperforms its peers within this category, suggesting
    superior efficiency or innovative strategies despite resource constraints. Further
    investigation into Company H reveals that its higher market adaptability is driven
    by its strategic focus on AI integration in preventive care devices, which aligns
    with its innovative product portfolio and the increasing demand for advanced healthcare
    solutions. Additionally, its low-to-medium risk preference facilitates targeted
    AI investments (6% of revenue) while maintaining operational stability, enabling
    it to achieve greater adaptability even under resource-limited conditions.'
  id: totrans-128
  prefs: []
  type: TYPE_NORMAL
  zh: 图 [12](https://arxiv.org/html/2411.15356v2#S4.F12 "图 12 ‣ 4.4 模块评估与敏感性结果 ‣ 4
    结果 ‣ 监管者-制造商 AI 代理建模：基于反馈驱动的多代理 LLM 框架") 显示了每家公司在经过 73 个时间步后的市场适应性，突出了它们战略决策和合规资源分配的结果。纵轴表示市场适应性，横轴则按公司（A–J）分类。属于资源丰富类别的公司（例如
    A、B 和 J）通常能够获得最高的适应性分数，强调了充足资源在促进战略灵活性和应对市场动态中的优势。相反，属于资源有限类别的公司（例如 C、D、H 和 I）的适应性明显较低，且在这些公司之间存在显著的差异。值得注意的是，H
    公司在这一类别中表现优于其他同行，表明尽管资源有限，它在效率或创新策略方面表现出色。进一步调查 H 公司发现，它较高的市场适应性源于其在预防性护理设备中整合人工智能的战略重点，这一策略与其创新的产品组合以及对先进医疗保健解决方案日益增长的需求相契合。此外，它的低至中等风险偏好使得其可以有针对性地进行人工智能投资（占收入的
    6%），同时保持运营稳定，从而在资源有限的条件下仍能获得更高的适应性。
- en: '![Refer to caption](img/cd8437b55186160e3cf723a24078f004.png)'
  id: totrans-129
  prefs: []
  type: TYPE_IMG
  zh: '![参见标题说明](img/cd8437b55186160e3cf723a24078f004.png)'
- en: 'Figure 9: Analysis of Market Adaptability Value Distribution'
  id: totrans-130
  prefs: []
  type: TYPE_NORMAL
  zh: 图 9：市场适应性价值分布分析
- en: 4.3 Decision made by Authority Agent
  id: totrans-131
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 4.3 权威代理作出的决策
- en: The ”Benefit-Risk Ratio” (BRR) serves as a foundational metric in regulatory
    decision-making, enabling authorities to assess whether a product’s potential
    benefits outweigh its associated risks sufficiently to justify market entry or
    continued presence. This ratio acts as a quantitative and qualitative guide for
    balancing innovation and safety, especially in highly regulated industries such
    as healthcare, where public safety and efficacy are paramount. By analyzing BRR,
    regulatory bodies can evaluate complex scenarios involving diverse manufacturers,
    varying product types, and evolving market dynamics.
  id: totrans-132
  prefs: []
  type: TYPE_NORMAL
  zh: “收益-风险比”（BRR）作为监管决策中的基础性指标，帮助监管机构评估产品的潜在收益是否足以抵消其相关风险，从而决定是否批准产品进入市场或继续存在。这个比率为平衡创新与安全提供了定量和定性指导，尤其在公共安全和有效性至关重要的高度监管行业，如医疗保健领域尤为重要。通过分析BRR，监管机构能够评估涉及多个制造商、不同产品类型和不断变化的市场动态的复杂情形。
- en: The authority agent take the BRR tool allows the authority to assess the overall
    market landscape, including the number of manufacturers present and the diversity
    of their products. Based on this comprehensive review, the authority agent sets
    a decision threshold to determine the acceptable level of benefit relative to
    risk for products entering or remaining in the market. Unlike real-world regulatory
    practices, where decisions are made on a case-by-case basis with significant flexibility
    for individual product characteristics, the authority agent in this model introduces
    a dynamic thresholding mechanism.
  id: totrans-133
  prefs: []
  type: TYPE_NORMAL
  zh: 权威代理使用BRR工具，使得监管机构能够评估整体市场格局，包括市场中制造商的数量及其产品的多样性。基于这一综合评审，权威代理设置决策阈值，确定产品进入或停留在市场中时可接受的收益与风险水平。与现实中的监管实践不同，后者通常根据具体个案作出决策并具有较大灵活性，允许考虑产品的个别特征，而该模型中的权威代理引入了一个动态阈值机制。
- en: 'As shown in Figure [10](https://arxiv.org/html/2411.15356v2#S4.F10 "Figure
    10 ‣ 4.3 Decision made by Authority Agent ‣ 4 Results ‣ Regulator-Manufacturer
    AI Agents Modeling: Mathematical Feedback-Driven Multi-Agent LLM Framework"),
    the threshold set by the authority agent is not a fixed value but fluctuates over
    time, reflecting adaptive decision-making based on changing market conditions.
    The fluctuation in the threshold ensures responsiveness to variations in market
    dynamics, such as the entry of new manufacturers or changes in product benefit-risk
    profiles. This dynamic approach mirrors real-life regulatory flexibility, where
    decisions often account for context-specific factors and evolving market realities.
    By analyzing the threshold trajectory, we observe a balance between maintaining
    rigorous standards and allowing flexibility to accommodate innovation and market
    diversity. The adaptive nature of the authority’s decision-making underscores
    the importance of balancing regulatory consistency with the need for situational
    responsiveness in complex and competitive markets.'
  id: totrans-134
  prefs: []
  type: TYPE_NORMAL
  zh: 如图[10](https://arxiv.org/html/2411.15356v2#S4.F10 "图 10 ‣ 4.3 权威代理做出的决策 ‣ 4
    结果 ‣ 调节者-制造商AI代理建模：基于数学反馈的多智能体LLM框架")所示，权威代理设置的阈值不是一个固定值，而是随着时间波动，反映了基于市场变化条件的适应性决策。阈值的波动确保了对市场动态变化的响应，例如新制造商的进入或产品效益-风险特征的变化。这种动态方法类似于现实中的监管灵活性，决策通常需要考虑特定情境的因素和不断变化的市场现实。通过分析阈值的轨迹，我们可以观察到，在维持严格标准的同时，也允许一定的灵活性以适应创新和市场多样性。权威决策的适应性本质强调了在复杂和竞争激烈的市场中，平衡监管一致性与情境响应需求的重要性。
- en: '![Refer to caption](img/bf41bbd5df5401994ef53315ee449c2d.png)'
  id: totrans-135
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明](img/bf41bbd5df5401994ef53315ee449c2d.png)'
- en: 'Figure 10: BRR value change set by multi agent framework'
  id: totrans-136
  prefs: []
  type: TYPE_NORMAL
  zh: 图 10：由多智能体框架设置的BRR值变化集
- en: 4.4 Module evaluation and sensitivity result
  id: totrans-137
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 4.4 模块评估与敏感性结果
- en: 'To validate the robustness and relevance of the framework, we conducted a comprehensive
    sensitivity analysis. The results are summarized and depicted in Figure [12](https://arxiv.org/html/2411.15356v2#S4.F12
    "Figure 12 ‣ 4.4 Module evaluation and sensitivity result ‣ 4 Results ‣ Regulator-Manufacturer
    AI Agents Modeling: Mathematical Feedback-Driven Multi-Agent LLM Framework"),
    showcasing the change rates for each key parameter across critical outputs: Guidance
    Issuance Rate ($G_{i}$), Compliance Effort ($C_{m}$), Market Adaptation ($M_{m}$),
    and Manufacturer Feedback ($F_{m}$).'
  id: totrans-138
  prefs: []
  type: TYPE_NORMAL
  zh: 为了验证框架的稳健性和相关性，我们进行了全面的敏感性分析。结果总结并展示在图[12](https://arxiv.org/html/2411.15356v2#S4.F12
    "图 12 ‣ 4.4 模块评估与敏感性结果 ‣ 4 结果 ‣ 调节者-制造商AI代理建模：基于数学反馈的多智能体LLM框架")中，展示了每个关键参数在主要输出：引导发布率($G_{i}$)、合规努力($C_{m}$)、市场适应性($M_{m}$)和制造商反馈($F_{m}$)中的变化率。
- en: '![Refer to caption](img/8d9f5408b9ddb13a4a1e8159fda035f8.png)'
  id: totrans-139
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明](img/8d9f5408b9ddb13a4a1e8159fda035f8.png)'
- en: 'Figure 11: Evaluation result of Guidance adherence analysis and compliance
    stability analysis'
  id: totrans-140
  prefs: []
  type: TYPE_NORMAL
  zh: 图 11：引导遵从性分析与合规稳定性分析的评估结果
- en: '![Refer to caption](img/b280f4e9acb1b30c95390956f1c4a5e6.png)'
  id: totrans-141
  prefs: []
  type: TYPE_IMG
  zh: '![参见说明](img/b280f4e9acb1b30c95390956f1c4a5e6.png)'
- en: 'Figure 12: Figure: Analysis of Parameter Sensitivity and Value Distribution'
  id: totrans-142
  prefs: []
  type: TYPE_NORMAL
  zh: 图 12：图：参数敏感性和数值分布分析
- en: 4.5 Sensitive analysis
  id: totrans-143
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
  zh: 4.5 敏感性分析
- en: Impact of Parameters on Model Outputs
  id: totrans-144
  prefs:
  - PREF_H5
  type: TYPE_NORMAL
  zh: 参数对模型输出的影响
- en: The parameters $\alpha_{1}$, $\phi_{1}$, and $\beta_{1}$, which govern the Guidance
    Issuance Rate, exhibited a moderate to strong influence on $G_{i}$, with changes
    leading to both positive and negative shifts in output. Notably, increasing $\alpha_{1}$
    from 0.1 to 0.2 resulted in significant increases in $G_{i}$, suggesting that
    regulatory guidance is sensitive to changes in the maximum issuance rate. Parameters
    such as $\phi_{2}$ and $\beta_{2}$, which influence Compliance Effort ($C_{m}$),
    demonstrated non-linear impacts. For instance, as $\phi_{2}$ increased, there
    was a notable positive effect on $C_{m}$, indicating that research and development
    investments have a pronounced impact on compliance behavior.
  id: totrans-145
  prefs: []
  type: TYPE_NORMAL
  zh: 控制引导发布率的参数$\alpha_{1}$、$\phi_{1}$和$\beta_{1}$对$G_{i}$表现出中等到强烈的影响，变化导致输出出现正负波动。值得注意的是，将$\alpha_{1}$从0.1增加到0.2显著提高了$G_{i}$，这表明监管引导对最大发布率的变化非常敏感。像$\phi_{2}$和$\beta_{2}$这类影响合规努力($C_{m}$)的参数则表现出非线性影响。例如，随着$\phi_{2}$的增加，$C_{m}$表现出显著的正向影响，表明研发投资对合规行为有着显著影响。
- en: The sensitivity of Market Adaptation ($M_{m}$) was most pronounced with variations
    in $\alpha_{3}$ and $\beta_{3}$. Specifically, higher values of $\alpha_{3}$ accelerated
    the rate at which compliance efforts translated into market adaptation, confirming
    the importance of resource allocation in this aspect. Feedback from manufacturers
    ($F_{m}$) was shown to be moderately influenced by adjustments in $\alpha_{4}$
    and $\phi_{4}$, which indicates the role of market adaptation and compliance capability
    in shaping feedback dynamics.
  id: totrans-146
  prefs: []
  type: TYPE_NORMAL
  zh: '市场适应性（$M_{m}$）对$\alpha_{3}$和$\beta_{3}$的变化最为敏感。具体而言，$\alpha_{3}$的较高值加快了合规努力转化为市场适应的速率，证明了资源配置在这一方面的重要性。制造商的反馈（$F_{m}$）显示出受$\alpha_{4}$和$\phi_{4}$调整的中等影响，这表明市场适应性和合规能力在塑造反馈动态中的作用。  '
- en: Critical Parameters and Their Influence
  id: totrans-147
  prefs:
  - PREF_H5
  type: TYPE_NORMAL
  zh: '关键参数及其影响  '
- en: Parameters like $\alpha_{1}$, $\alpha_{2}$, and $\alpha_{3}$ were identified
    as critical, with relatively large change rates in key outputs when adjusted.
    This finding emphasizes the importance of accurately estimating these parameters,
    as they significantly drive the regulatory flow and market response dynamics.
    Conversely, some parameters, such as $\gamma_{1}$ and $\gamma_{2}$, showed more
    stable behavior, suggesting lower sensitivity. This implies that while these parameters
    are still relevant, their precise values may be less crucial for overall model
    performance, which could simplify parameter estimation.
  id: totrans-148
  prefs: []
  type: TYPE_NORMAL
  zh: '如$\alpha_{1}$、$\alpha_{2}$和$\alpha_{3}$等参数被识别为关键参数，在调整时它们对关键输出的变化率较大。这一发现强调了准确估算这些参数的重要性，因为它们显著驱动着监管流程和市场响应动态。相反，一些参数，如$\gamma_{1}$和$\gamma_{2}$，表现出较为稳定的行为，表明其敏感度较低。这意味着尽管这些参数仍然相关，但它们的精确值可能对整体模型性能的影响较小，从而简化了参数估算。  '
- en: Non-linear and Asymmetric Effects
  id: totrans-149
  prefs:
  - PREF_H5
  type: TYPE_NORMAL
  zh: '非线性与不对称效应  '
- en: The analysis revealed that the effects of parameter changes are often non-linear
    and asymmetric. For example, increasing $\beta_{1}$ resulted in diminishing marginal
    impacts on $G_{i}$, demonstrating a saturation effect. Similarly, variations in
    $\phi_{3}$ had asymmetric impacts on $M_{m}$, which highlights the need for careful
    tuning to avoid disproportionate responses.
  id: totrans-150
  prefs: []
  type: TYPE_NORMAL
  zh: '分析表明，参数变化的影响通常是非线性和不对称的。例如，增加$\beta_{1}$会导致$G_{i}$的边际影响递减，表现出饱和效应。类似地，$\phi_{3}$的变化对$M_{m}$产生了不对称的影响，这强调了需要谨慎调整，以避免不成比例的反应。  '
- en: The results of our sensitivity analysis validate the robustness of our model,
    as it consistently exhibited expected and explainable behaviors across a wide
    range of parameter variations. The identification of critical parameters underscores
    the importance of focusing on these variables during calibration and further analysis.
    Additionally, the non-linear responses observed suggest that our model captures
    the complex dynamics of regulatory and market interactions effectively.
  id: totrans-151
  prefs: []
  type: TYPE_NORMAL
  zh: '我们的敏感性分析结果验证了模型的稳健性，因为它在广泛的参数变化范围内始终展现出预期且可解释的行为。识别关键参数强调了在标定和进一步分析过程中专注于这些变量的重要性。此外，观察到的非线性反应表明，我们的模型有效地捕捉了监管与市场互动的复杂动态。  '
- en: While the sensitivity analysis provides valuable insights, it does not replace
    empirical validation against real-world data. Future work should include extensive
    data collection to refine parameter estimates and validate model predictions.
    Additionally, exploring more advanced sensitivity analysis techniques, such as
    global sensitivity analysis, could provide a more comprehensive understanding
    of model dynamics.
  id: totrans-152
  prefs: []
  type: TYPE_NORMAL
  zh: 虽然敏感性分析提供了有价值的见解，但它并不能替代与现实数据的实证验证。未来的工作应包括广泛的数据收集，以优化参数估算并验证模型预测。此外，探索更先进的敏感性分析技术，如全局敏感性分析，可以提供对模型动态更全面的理解。
- en: 5 Discussion
  id: totrans-153
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: '5 讨论  '
- en: This study introduces a multi-agent framework designed to model regulatory compliance
    and market adaptation dynamics in the medical device industry. By simulating the
    interactions between regulatory bodies and manufacturers, the framework provides
    a novel lens to examine policy impacts, strategic decision-making, and adaptive
    behaviors. Despite its utility, the model entails certain limitations that warrant
    further investigation and refinement to enhance its robustness and applicability
    in real-world settings.
  id: totrans-154
  prefs: []
  type: TYPE_NORMAL
  zh: 本研究引入了一个多智能体框架，旨在模拟医疗器械行业中的监管合规性和市场适应动态。通过模拟监管机构和制造商之间的互动，该框架为检验政策影响、战略决策和适应行为提供了新的视角。尽管该模型具有一定的实用性，但它也存在一些局限性，需要进一步研究和改进，以增强其在实际环境中的稳健性和适用性。
- en: Regulatory policy analysis could benefit significantly from this modeling approach.
    Regulatory bodies might employ the model to simulate the potential impact of new
    policies on the medical device industry. By adjusting parameters such as $\alpha_{1}$,
    $\beta_{1}$, and $\phi_{1}$ in Equation (1), regulators could model scenarios
    involving varying guidance rates and their effects on compliance efforts and market
    adaptation. While this predictive capability could enable more informed policy-making,
    ensuring that regulations are both effective and balanced, the accuracy of these
    predictions depends heavily on the quality and completeness of input data, which
    is a limitation in real-world applications.
  id: totrans-155
  prefs: []
  type: TYPE_NORMAL
  zh: 监管政策分析可以从这种建模方法中受益匪浅。监管机构可以利用该模型模拟新政策对医疗器械行业的潜在影响。通过调整方程式（1）中的参数，例如$\alpha_{1}$、$\beta_{1}$和$\phi_{1}$，监管者可以模拟涉及不同指导率的情景，并分析其对合规努力和市场适应的影响。尽管这种预测能力能够促进更加明智的政策制定，确保法规既有效又平衡，但这些预测的准确性在很大程度上依赖于输入数据的质量和完整性，而这是现实应用中的一大局限。
- en: The model holds potential for strategic planning for manufacturers. Medical
    device manufacturers could leverage the framework to anticipate regulatory changes
    and adjust compliance strategies proactively. By inputting specific data—such
    as compliance scores, R&D investments, and market share—the model might enable
    companies to forecast future compliance costs and evaluate market adaptation strategies.
    However, the variability of real-world conditions, such as sudden regulatory changes
    or market disruptions, limits the precision of these forecasts, making the model
    better suited for strategic guidance rather than exact predictions. It also serves
    as a basis for academic Research and Validation. Researchers could explore the
    broader implications of regulatory impacts within the medtech industry by using
    this framework. Sensitivity analyses and validations using real-world data could
    provide valuable insights into its robustness and applicability. However, the
    model’s current limitations, such as assumptions of uniform compliance behavior
    or simplified market dynamics, must be addressed to improve its credibility and
    generalizability. The model aspires to support industry benchmarking. By comparing
    predicted compliance efforts and market adaptation outcomes with actual industry
    performance, companies could identify performance gaps and opportunities for improvement.
    This process might facilitate the establishment of industry standards and promote
    continuous improvement. However, the model’s inherent simplifications might limit
    its ability to capture the nuanced, firm-specific factors that drive real-world
    performance, reducing its effectiveness as a benchmarking tool in its current
    state.
  id: totrans-156
  prefs: []
  type: TYPE_NORMAL
  zh: 该模型对制造商的战略规划具有潜力。医疗器械制造商可以利用该框架预测监管变化，并主动调整合规策略。通过输入特定数据——如合规得分、研发投资和市场份额——该模型可能帮助企业预测未来的合规成本并评估市场适应策略。然而，现实世界条件的变动性，例如突如其来的监管变化或市场中断，限制了这些预测的精确性，使得该模型更适合用于战略指导，而非精确预测。它还为学术研究和验证提供了基础。研究人员可以利用该框架探索监管影响在医疗技术行业中的广泛意义。使用真实世界数据进行敏感性分析和验证可以为其稳健性和适用性提供宝贵的见解。然而，模型当前的局限性，如假设统一的合规行为或简化的市场动态，必须得到解决，以提高其可信度和普适性。该模型旨在支持行业基准。通过将预测的合规努力和市场适应结果与实际行业表现进行比较，企业可以识别绩效差距和改进机会。这个过程可能有助于建立行业标准并推动持续改进。然而，模型固有的简化可能限制其捕捉推动现实世界绩效的公司特定因素的能力，降低了其作为基准工具在当前状态下的有效性。
- en: 6 Limitation
  id: totrans-157
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 6 限制
- en: The primary limitation of this study stems from the simplifications inherent
    to the BRR (Benefit Risk Ratio) scoring system, which leverages large language
    model to assign scores based on manufacturers’ profiles, device descriptions,
    and regulatory environments. While the BRR system employs logical principles grounded
    in regulatory decision-making processes, it remains a proxy for real-world evaluations,
    which are inherently more complex and multifaceted.
  id: totrans-158
  prefs: []
  type: TYPE_NORMAL
  zh: 本研究的主要局限性来自于BRR（效益风险比）评分系统固有的简化，该系统利用大型语言模型根据制造商的档案、设备描述和监管环境分配分数。尽管BRR系统采用了基于监管决策过程的逻辑原则，但它仍然是对现实世界评估的代理，后者本质上更加复杂和多维。
- en: In practice, the BRR consideration and final approval of medical devices are
    influenced by a wide range of additional factors, including clinical trial results,
    post-market surveillance data, performance in animal studies, laboratory testing
    outcomes, and urgent medical needs. For example, evaluating a cardiac implantable
    device in real-world conditions requires assessing its long-term clinical effectiveness,
    biocompatibility, and cost-efficiency, as well as its alignment with reimbursement
    policies and patient-centered outcomes. These complexities go beyond the scope
    of the current model, which relies mainly on structured input features and generalized
    decision-making rules.
  id: totrans-159
  prefs: []
  type: TYPE_NORMAL
  zh: 在实践中，BRR对医疗设备的考虑和最终批准受到许多其他因素的影响，包括临床试验结果、上市后监测数据、动物研究中的表现、实验室测试结果以及紧急医疗需求。例如，评估一个心脏植入设备在现实条件下的表现需要评估其长期临床效果、生物兼容性和成本效益，同时还要考虑其与报销政策和以患者为中心的结果的对接。这些复杂性超出了当前模型的范围，当前模型主要依赖于结构化输入特征和通用的决策规则。
- en: This study represents a foundational step in developing a quantitative framework
    for modeling regulatory compliance and market adaptation. As a first attempt,
    it necessarily abstracts away certain product-specific and firm-specific details
    to maintain computational tractability and generalizability. Future work can build
    on this foundation by integrating individual attributes of the granular product
    and real-world data sources to improve the accuracy and scope of the model.
  id: totrans-160
  prefs: []
  type: TYPE_NORMAL
  zh: 本研究代表了开发量化框架以建模监管合规性和市场适应性的基础性步骤。作为首次尝试，它必然会抽象掉某些产品特定和公司特定的细节，以保持计算的可处理性和普适性。未来的工作可以在此基础上进行扩展，通过整合更细化的产品特征和现实世界数据来源，来提高模型的准确性和适用范围。
- en: 7 Conclusion and Future Work
  id: totrans-161
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 7 结论与未来工作
- en: In this paper, we introduced a novel simulation multi agent LLM framework designed
    to evaluate and enhance regulatory compliance strategies for AI-based medical
    device manufacturers. By representing both manufacturers and regulatory bodies,
    such as the FDA, as autonomous agents powered by large language models, this framework
    enables iterative, interactive compliance assessments that mimic real-world regulatory
    processes. Our approach provides a unique solution to address the regulatory complexities
    associated with the adaptive nature of AI in medical devices, where compliance
    is a dynamic and ongoing challenge. The metrics of this system, including compliance
    accuracy, stability, and compliance with regulatory guidance, allow a multidimensional
    view of compliance performance. Experimental results demonstrated that this iterative
    learning environment enables manufacturers to continuously refine compliance strategies,
    while regulatory agents can provide tailored feedback to guide manufacturers toward
    optimal compliance. Such a setup not only reduces potential compliance risks but
    also promotes faster and more efficient market readiness for innovative AI-based
    medical devices. Beyond its immediate application in medical device compliance,
    this framework has broader potential in various high-regulation industries, including
    financial technology, biopharmaceuticals, and autonomous vehicles. It represents
    a significant step forward in simulating and analyzing regulatory compliance for
    AI-driven technologies. It lays the groundwork for proactive compliance assessment,
    fosters better alignment with regulatory standards, and enhances safety and efficacy
    in AI applications. As such, it offers a promising pathway for advancing the role
    of AI-powered agent systems in regulatory science, while opening avenues for cross-disciplinary
    research and collaboration across sectors that prioritize safety, compliance,
    and innovation.
  id: totrans-162
  prefs: []
  type: TYPE_NORMAL
  zh: 在本文中，我们介绍了一种新颖的模拟多智能体大语言模型（LLM）框架，旨在评估和增强基于AI的医疗器械制造商的合规性策略。通过将制造商和监管机构（如FDA）表示为由大语言模型驱动的自主智能体，该框架实现了迭代、互动的合规性评估，模拟了现实世界中的监管流程。我们的方法为解决与医疗器械中AI的适应性特性相关的监管复杂性提供了独特的解决方案，因为合规性是一个动态且持续的挑战。该系统的指标，包括合规准确性、稳定性和遵循监管指导的程度，提供了合规性表现的多维视角。实验结果表明，这种迭代学习环境使制造商能够不断优化合规策略，而监管智能体则能提供定制化的反馈，帮助制造商朝着最佳合规性方向发展。这样的设置不仅降低了潜在的合规风险，还促进了创新型AI医疗器械的更快、更高效的市场准备。除了在医疗器械合规性方面的即时应用外，该框架在各类高监管行业中也具有更广泛的潜力，包括金融科技、生物制药和自动驾驶汽车。它代表了在模拟和分析AI驱动技术的监管合规性方面的重要进展，为主动合规评估奠定了基础，促进了与监管标准的更好对接，并增强了AI应用的安全性和有效性。因此，它为推动AI驱动的智能体系统在监管科学中的作用提供了有前景的路径，同时也为跨学科的研究和行业间的合作打开了新的大门，这些领域优先考虑安全性、合规性和创新。
- en: References
  id: totrans-163
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 参考文献
- en: '[1] Y. Han and J. Bergmann, “Transforming medical regulations into numbers:
    Vectorizing a decade of medical device regulatory shifts in the usa, eu, and china,”
    *arXiv preprint arXiv:2411.00567*, 2024.'
  id: totrans-164
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[1] Y. Han 和 J. Bergmann, “将医疗法规转化为数字：将美国、欧盟和中国十年的医疗器械法规变化向量化，” *arXiv预印本arXiv:2411.00567*，2024。'
- en: '[2] D. B. Kramer, S. Xu, and A. S. Kesselheim, “How does medical device regulation
    perform in the united states and the european union? a systematic review,” 2012.'
  id: totrans-165
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[2] D. B. Kramer, S. Xu 和 A. S. Kesselheim, “美国和欧盟的医疗器械监管表现如何？一项系统评审，” 2012。'
- en: '[3] Y. Han, A. Ceross, F. Bourgeois, P. Savaget, and J. H. Bergmann, “Evaluation
    of large language models for the classification of medical device software,” 2024.'
  id: totrans-166
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[3] Y. Han, A. Ceross, F. Bourgeois, P. Savaget, 和 J. H. Bergmann, “大语言模型在医疗器械软件分类中的评估，”
    2024。'
- en: '[4] P. Anderson, “Perspective: Complexity theory and organization science,”
    *Organization science*, vol. 10, no. 3, pp. 216–232, 1999.'
  id: totrans-167
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[4] P. Anderson, “观点：复杂性理论与组织科学，” *组织科学*，第10卷，第3期，216–232页，1999。'
- en: '[5] J. D. Sterman, “Business dynamics: Systems thinking and modeling for a
    complex world,” *MacGraw-Hill Company*, 2000.'
  id: totrans-168
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[5] J. D. Sterman, “商业动态：复杂世界的系统思维与建模，” *MacGraw-Hill出版社*，2000。'
- en: '[6] S. A. Kauffman, *The origins of order: Self-organization and selection
    in evolution*.   Oxford University Press, 1993.'
  id: totrans-169
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[6] S. A. Kauffman, *秩序的起源：进化中的自组织与选择*。牛津大学出版社，1993。'
- en: '[7] D. Helbing and S. Balietti, “How to do agent-based simulations in the future:
    From modeling social mechanisms to emergent phenomena and interactive systems
    design,” *Urban Economics & Regional Studies eJournal*, 2013. [Online]. Available:
    [https://api.semanticscholar.org/CorpusID:5752779](https://api.semanticscholar.org/CorpusID:5752779)'
  id: totrans-170
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[7] D. Helbing 和 S. Balietti，“未来如何进行基于代理的仿真：从建模社会机制到涌现现象和互动系统设计，”*城市经济学与区域研究电子期刊*，2013年。[在线]。可用链接：[https://api.semanticscholar.org/CorpusID:5752779](https://api.semanticscholar.org/CorpusID:5752779)'
- en: '[8] A. E. Lottes, K. J. Cavanaugh, Y. Y.-F. Chan, V. J. Devlin, C. J. Goergen,
    R. Jean, J. C. Linnes, M. Malone, R. Peat, D. G. Reuter *et al.*, “Navigating
    the regulatory pathway for medical devices—a conversation with the fda, clinicians,
    researchers, and industry experts,” *Journal of Cardiovascular Translational Research*,
    vol. 15, no. 5, pp. 927–943, 2022.'
  id: totrans-171
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[8] A. E. Lottes, K. J. Cavanaugh, Y. Y.-F. Chan, V. J. Devlin, C. J. Goergen,
    R. Jean, J. C. Linnes, M. Malone, R. Peat, D. G. Reuter *等*，“医疗器械的监管路径导航——与 FDA、临床医生、研究人员和行业专家的对话，”*心血管转化研究杂志*，第15卷，第5期，第927–943页，2022年。'
- en: '[9] M. Wooldridge, *An introduction to multiagent systems*.   John wiley &
    sons, 2009.'
  id: totrans-172
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[9] M. Wooldridge，*多智能体系统导论*。John Wiley & Sons，2009年。'
- en: '[10] D. C. Parker, S. M. Manson, M. A. Janssen, M. J. Hoffmann, and P. Deadman,
    “Multi-agent systems for the simulation of land-use and land-cover change: a review,”
    *Annals of the association of American Geographers*, vol. 93, no. 2, pp. 314–337,
    2003.'
  id: totrans-173
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[10] D. C. Parker, S. M. Manson, M. A. Janssen, M. J. Hoffmann 和 P. Deadman，“用于土地利用和土地覆盖变化仿真的多智能体系统：一项综述，”*美国地理学会年鉴*，第93卷，第2期，第314–337页，2003年。'
- en: '[11] L. Liu, M. Wang, M.-O. Pun, and X. Xiong, “A multi-agent rollout approach
    for highway bottleneck decongenston in mixed autonomy,” *arXiv preprint arXiv:2405.03132*,
    2024.'
  id: totrans-174
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[11] L. Liu, M. Wang, M.-O. Pun 和 X. Xiong，“一种用于混合自主环境下高速公路瓶颈疏解的多代理滚动方法，”*arXiv
    预印本 arXiv:2405.03132*，2024年。'
- en: '[12] J. Xie, Z. Chen, R. Zhang, X. Wan, and G. Li, “Large multimodal agents:
    A survey,” *arXiv preprint arXiv:2402.15116*, 2024.'
  id: totrans-175
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[12] J. Xie, Z. Chen, R. Zhang, X. Wan 和 G. Li，“大型多模态智能体：一项综述，”*arXiv 预印本 arXiv:2402.15116*，2024年。'
- en: '[13] T. Guo, X. Chen, Y. Wang, R. Chang, S. Pei, N. V. Chawla, O. Wiest, and
    X. Zhang, “Large language model based multi-agents: A survey of progress and challenges,”
    *arXiv preprint arXiv:2402.01680*, 2024.'
  id: totrans-176
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[13] T. Guo, X. Chen, Y. Wang, R. Chang, S. Pei, N. V. Chawla, O. Wiest 和 X.
    Zhang，“基于大型语言模型的多智能体：进展与挑战的综述，”*arXiv 预印本 arXiv:2402.01680*，2024年。'
- en: '[14] J. R. Turner and R. M. Baker, “Complexity theory: An overview with potential
    applications for the social sciences,” *Systems*, vol. 7, no. 1, p. 4, 2019.'
  id: totrans-177
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[14] J. R. Turner 和 R. M. Baker，“复杂性理论：概述与其在社会科学中的潜在应用，”*系统*，第7卷，第1期，第4页，2019年。'
- en: '[15] C. M. Macal, “Everything you need to know about agent-based modelling
    and simulation,” *Journal of Simulation*, vol. 10, pp. 144–156, 2016.'
  id: totrans-178
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[15] C. M. Macal，“关于基于代理的建模与仿真的一切你需要知道的，”*仿真期刊*，第10卷，第144–156页，2016年。'
- en: '[16] R. Axelrod and M. D. Cohen, *Harnessing complexity*.   Basic books, 2008.'
  id: totrans-179
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[16] R. Axelrod 和 M. D. Cohen，*驾驭复杂性*。Basic Books，2008年。'
- en: '[17] P. Hedström and P. Ylikoski, “Causal mechanisms in the social sciences,”
    *Annual review of sociology*, vol. 36, pp. 49–67, 2010.'
  id: totrans-180
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[17] P. Hedström 和 P. Ylikoski，“社会科学中的因果机制，”*社会学年鉴*，第36卷，第49–67页，2010年。'
- en: '[18] Y. Wang, L. Liu, M. Wang, and X. Xiong, “Reinforcement learning from human
    feedback for lane changing of autonomous vehicles in mixed traffic,” *arXiv preprint
    arXiv:2408.04447*, 2024.'
  id: totrans-181
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[18] Y. Wang, L. Liu, M. Wang, 和 X. Xiong，“基于人类反馈的强化学习用于混合交通中的自动驾驶车辆车道变换，”*arXiv
    预印本 arXiv:2408.04447*，2024年。'
- en: '[19] J. R. Turner, “Editor’s commentary: regulatory science and the science
    of safety,” *Drug Information Journal*, vol. 45, no. 3, pp. 221–227, 2011.'
  id: totrans-182
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[19] J. R. Turner，“编辑评论：监管科学与安全科学，”*药物信息期刊*，第45卷，第3期，第221–227页，2011年。'
- en: '[20] Y. Han, A. Ceross, and J. Bergmann, “More than red tape: exploring complexity
    in medical device regulatory affairs,” *Frontiers in Medicine*, vol. 11, p. 1415319,
    2024.'
  id: totrans-183
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[20] Y. Han, A. Ceross 和 J. Bergmann，“不止是繁文缛节：探索医疗器械监管事务中的复杂性，”*医学前沿*，第11卷，第1415319页，2024年。'
- en: '[21] Y. Han and J. Tao, “Revolutionizing pharma: Unveiling the ai and llm trends
    in the pharmaceutical industry,” *arXiv preprint arXiv:2401.10273*, 2024.'
  id: totrans-184
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[21] Y. Han 和 J. Tao，“革新制药：揭示制药行业中的 AI 和 LLM 趋势，”*arXiv 预印本 arXiv:2401.10273*，2024年。'
- en: '[22] Y. Han, A. Ceross, and J. H. M. Bergmann, “The use of readability metrics
    in legal text: A systematic literature review,” 2024.'
  id: totrans-185
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[22] Y. Han, A. Ceross 和 J. H. M. Bergmann，“法律文本中的可读性度量：一项系统的文献综述，”2024年。'
- en: '[23] C. Stillhart, X. Pepin, C. Tistaert, D. Good, A. Van Den Bergh, N. Parrott,
    and F. Kesisoglou, “Pbpk absorption modeling: establishing the in vitro–in vivo
    link—industry perspective,” *The AAPS Journal*, vol. 21, pp. 1–13, 2019.'
  id: totrans-186
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[23] C. Stillhart, X. Pepin, C. Tistaert, D. Good, A. Van Den Bergh, N. Parrott
    和 F. Kesisoglou，“Pbpk吸收建模：建立体外-体内连接—行业视角，” *AAPS杂志*，第21卷，第1-13页，2019年。'
- en: '[24] T. M. Morrison, P. Pathmanathan, M. Adwan, and E. Margerrison, “Advancing
    regulatory science with computational modeling for medical devices at the fda’s
    office of science and engineering laboratories,” *Frontiers in medicine*, vol. 5,
    p. 241, 2018.'
  id: totrans-187
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[24] T. M. Morrison, P. Pathmanathan, M. Adwan 和 E. Margerrison，“通过FDA科学与工程实验室推进医疗器械的计算建模监管科学，”
    *医学前沿*，第5卷，第241页，2018年。'
- en: '[25] T. O’Neill, R. Miksad, D. Miller, L. Maloney, A. John, C. Hiller, and
    J. Hornberger, “Ispor, the fda, and the evolving regulatory science of medical
    device products,” *Value in Health*, vol. 22, no. 7, pp. 754–761, 2019.'
  id: totrans-188
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[25] T. O’Neill, R. Miksad, D. Miller, L. Maloney, A. John, C. Hiller, 和 J.
    Hornberger，“ISPOR、FDA与医疗器械产品的不断发展的监管科学，” *健康价值*，第22卷，第7期，第754-761页，2019年。'
- en: '[26] Y. Wang, A. Guan, S. Wickramasekara, and K. S. Phillips, “Analytical chemistry
    in the regulatory science of medical devices,” *Annual Review of Analytical Chemistry*,
    vol. 11, no. 1, pp. 307–327, 2018.'
  id: totrans-189
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[26] Y. Wang, A. Guan, S. Wickramasekara 和 K. S. Phillips，“医学器械监管科学中的分析化学，”
    *分析化学年评*，第11卷，第1期，第307-327页，2018年。'
- en: '[27] International Conference on Harmonisation of Technical Requirements for
    Registration of Pharmaceuticals for Human Use, “ICH Harmonised Tripartite Guideline:
    Quality Risk Management Q9,” International Conference on Harmonisation of Technical
    Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland,
    Tech. Rep., 2005.'
  id: totrans-190
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[27] 人用药品注册技术要求国际协调会议，“ICH协调三方指南：质量风险管理Q9，” 人用药品注册技术要求国际协调会议，瑞士日内瓦，技术报告，2005年。'
- en: '[28] U. FDA, “Guidance for industry: Q10 quality systems approach to pharmaceutical
    cgmp regulations,” *Rockville, MD*, 2006.'
  id: totrans-191
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[28] U. FDA, “行业指南：Q10质量体系对药品cGMP法规的应用，” *马里兰州罗克维尔*，2006年。'
- en: '[29] M. E. Gonçalves, “The risk-based approach under the new eu data protection
    regulation: a critical perspective,” *Journal of Risk Research*, vol. 23, no. 2,
    pp. 139–152, 2020.'
  id: totrans-192
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[29] M. E. Gonçalves，“新欧盟数据保护法规下的风险基础方法：批判性视角，” *风险研究杂志*，第23卷，第2期，第139-152页，2020年。'
- en: '[30] M. Y. Smith, I. Benattia, C. Strauss, L. Bloss, and Q. Jiang, “Structured
    benefit-risk assessment across the product lifecycle: practical considerations,”
    *Therapeutic Innovation & Regulatory Science*, vol. 51, no. 4, pp. 501–508, 2017.'
  id: totrans-193
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[30] M. Y. Smith, I. Benattia, C. Strauss, L. Bloss 和 Q. Jiang，“跨产品生命周期的结构化效益-风险评估：实践中的考虑，”
    *治疗创新与监管科学*，第51卷，第4期，第501-508页，2017年。'
- en: '[31] M. C. Weinstein and W. B. Stason, “Foundations of cost-effectiveness analysis
    for health and medical practices,” *New England journal of medicine*, vol. 296,
    no. 13, pp. 716–721, 1977.'
  id: totrans-194
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[31] M. C. Weinstein 和 W. B. Stason，“健康与医学实践成本效益分析基础，” *新英格兰医学杂志*，第296卷，第13期，第716-721页，1977年。'
- en: '[32] M. F. Drummond, M. J. Sculpher, K. Claxton, G. L. Stoddart, and G. W.
    Torrance, *Methods for the economic evaluation of health care programmes*.   Oxford
    university press, 2015.'
  id: totrans-195
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[32] M. F. Drummond, M. J. Sculpher, K. Claxton, G. L. Stoddart, 和 G. W. Torrance，*医疗保健项目的经济评估方法*。牛津大学出版社，2015年。'
- en: '[33] X. Xiong, E. Xiao, and L. Jin, “Analysis of a stochastic model for coordinated
    platooning of heavy-duty vehicles,” in *2019 IEEE 58th conference on decision
    and control (CDC)*.   IEEE, 2019, pp. 3170–3175.'
  id: totrans-196
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[33] X. Xiong, E. Xiao 和 L. Jin，“重型车辆协调编队的随机模型分析，”在 *2019年IEEE第58届决策与控制会议（CDC）*。IEEE，2019年，第3170-3175页。'
- en: '[34] Y. Bao, N. Buhay, and Q. Zheng, “A dynamic model for gmp compliance and
    regulatory science,” *Journal of Pharmaceutical Innovation*, vol. 19, no. 3, pp.
    1–16, 2024.'
  id: totrans-197
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[34] Y. Bao, N. Buhay 和 Q. Zheng，“GMP合规性与监管科学的动态模型，” *药物创新杂志*，第19卷，第3期，第1-16页，2024年。'
- en: '[35] S. Gao, A. Fang, Y. Huang, V. Giunchiglia, A. Noori, J. R. Schwarz, Y. Ektefaie,
    J. Kondic, and M. Zitnik, “Empowering biomedical discovery with ai agents,” *Cell*,
    vol. 187, no. 22, pp. 6125–6151, 2024.'
  id: totrans-198
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[35] S. Gao, A. Fang, Y. Huang, V. Giunchiglia, A. Noori, J. R. Schwarz, Y.
    Ektefaie, J. Kondic 和 M. Zitnik，“利用AI代理赋能生物医学发现，” *Cell*，第187卷，第22期，第6125-6151页，2024年。'
- en: '[36] M.-L. Kürzinger, L. Douarin, I. Uzun, C. El-Haddad, W. Hurst, J. Juhaeri,
    and S. Tcherny-Lessenot, “Structured benefit–risk evaluation for medicinal products:
    review of quantitative benefit–risk assessment findings in the literature,” *Therapeutic
    Advances in Drug Safety*, vol. 11, p. 2042098620976951, 2020.'
  id: totrans-199
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[36] M.-L. Kürzinger, L. Douarin, I. Uzun, C. El-Haddad, W. Hurst, J. Juhaeri,
    和 S. Tcherny-Lessenot, “药品的结构化利益–风险评估：文献中定量利益–风险评估结果的回顾，” *药物安全性治疗进展*，第11卷，第2042098620976951页，2020年。'
- en: '[37] G. Li, H. Hammoud, H. Itani, D. Khizbullin, and B. Ghanem, “Camel: Communicative
    agents for” mind” exploration of large language model society,” *Advances in Neural
    Information Processing Systems*, vol. 36, pp. 51 991–52 008, 2023.'
  id: totrans-200
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[37] G. Li, H. Hammoud, H. Itani, D. Khizbullin, 和 B. Ghanem, “骆驼：用于大语言模型社会‘思维’探索的交流代理，”
    *神经信息处理系统进展*，第36卷，第51,991–52,008页，2023年。'
- en: '[38] P. F. Verhulst, *Notice sur la loi que la population suit dans son accroissement*.   Correspondance
    Mathématique et Physique, 1838.'
  id: totrans-201
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[38] P. F. Verhulst, *人口增长法则的通知*。《数学与物理学通讯》，1838年。'
- en: '[39] S. H. Strogatz, *Nonlinear Dynamics and Chaos: With Applications to Physics,
    Biology, Chemistry, and Engineering*.   CRC Press, 2018.'
  id: totrans-202
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[39] S. H. Strogatz, *非线性动力学与混沌：应用于物理学、生物学、化学和工程学*。CRC Press, 2018。'
- en: '[40] E. M. Rogers, *Diffusion of Innovations*.   Free Press, 2003.'
  id: totrans-203
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[40] E. M. Rogers, *创新扩散*。Free Press, 2003。'
- en: '[41] J. W. Forrester, *Principles of Systems*.   MIT Press, 1968.'
  id: totrans-204
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[41] J. W. Forrester, *系统原理*。MIT Press, 1968。'
- en: '[42] J. D. Murray, *Mathematical Biology I: An Introduction*.   Springer, 2002.'
  id: totrans-205
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[42] J. D. Murray, *数学生物学 I：导论*。Springer, 2002。'
- en: '[43] F. Ding, “Least squares parameter estimation and multi-innovation least
    squares methods for linear fitting problems from noisy data,” *Journal of Computational
    and Applied Mathematics*, vol. 426, p. 115107, 2023.'
  id: totrans-206
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: '[43] F. Ding, “最小二乘参数估计与基于噪声数据的线性拟合问题的多创新最小二乘方法，” *计算与应用数学杂志*，第426卷，第115107页，2023年。'
